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ABSTRACT 
 
JASON I. HERSCHKOWITZ: Breast Cancer Subtypes, Mouse Models, and Microarrays 
(Under the direction of Charles Perou) 
 
 
Breast cancer can no longer be viewed as a single disease.  Molecular profiling 
studies have altered the way we consider breast cancer, showing us that there are several 
subtypes, each with their own unique biology.  There are many model systems available in 
which to study breast cancer, however, each of these comes with advantages and 
disadvantages.  We chose the mouse as a model to investigate breast cancer biology because 
it gives us the ability to study tumor progression and response to therapy in vivo.  Numerous 
mouse models of breast carcinomas have been developed.  The extent to which any faithfully 
represent clinically significant human phenotypes was unknown. Analogous to our human 
studies, we characterized mammary tumor gene expression profiles from a large number of 
murine models using DNA microarrays and compared the resulting data to our human breast 
tumor dataset.  Two major applications of across-species tumor comparisons surfaced from 
these studies.  First, we were able to determine that mouse models contain many of the global 
characteristics of particular classes or subtypes of human tumors.  This included basal versus 
luminal distinctions, a proliferation/cell cycle signature, and a fibroblast signature.  Second, 
the mouse models were able to inform the human disease; for example, we identified an 
amplicon that included the K-ras gene present in both mouse and human basal tumors.  The 
high proliferation seen in common between mouse models of Rb loss and human basal-like 
breast tumors hinted that there is an Rb defect in this human subtype.  And finally the mouse 
 ii
spindloid tumors shared significant gene overlap with a new molecular subtype of breast 
cancer.  Although no single murine model recapitulated all the expression features of a given 
human subtype, these shared expression features have provided us a common framework so 
that we can now integrate these murine mammary tumor models into our studies of human 
breast cancer.
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CHAPTER I 
INTRODUCTION 
 
In women in the United States, breast cancer is currently the most commonly 
diagnosed tumor type, and the second leading cause of cancer death[1].  One in eight 
American women will develop this disease in their lifetime.  Some of the non-modifiable risk 
factors include age, family history, age at first full term pregnancy, early menarche, and late 
menopause.  Modifiable risk factors include postmenopausal obesity, use of postmenopausal 
hormones, alcohol consumption, and physical inactivity.  From cell lines to xenografts, there 
are many model systems to study breast cancer[2].  Each of these model systems comes with 
inherent advantages and disadvantages.  Different models may represent distinct aspects or 
subtypes of this heterogeneous disease and studying one model will never be adequate to 
encompass the whole disease.  My research has focused on the mouse because we desired a 
model that will give us the ability to study tumor formation, progression and therapy 
response in vivo.  Furthermore, the mouse is amenable to genetic manipulation.  There are 
many mouse mammary tumor models that have been generated over the past twenty years.  
In order to use these models in the most relevant way, the question we first need to answer is 
how do these mouse models relate to the human disease and more specifically, what tumor 
subtypes of breast cancer are represented by each model?  It is these models that most closely 
mimic the human disease that will be the most useful in further studies.
 
Breast cancer subtypes 
Classification of breast cancer into molecular subtypes using gene expression 
profiling has drastically changed our understanding of breast cancer biology[3-5].  Breast 
cancer can now be divided into at least five subtypes.  The biology of these subtypes is 
indicative of different cell types of origin.  Two of these subtypes are estrogen receptor (ER) 
negative: High expression of basal cytokeratins 5 and 17, reminiscent of normal breast 
basal/myoepithelial cells, is characteristic of the basal-like subtype.  HER2+/ER- tumors, 
which are the second ER- subtype, generally overexpress HER2 and often show 
amplification of this locus.  Two of these subtypes are ER-positive, with the Luminal A 
tumors expressing an important quartet of transcription factors (ER, GATA3, XBP1, and 
FOXA1)[6] as well as luminal cytokeratins 8 and 18.   Luminal B tumors express the same 
luminal cell type genes at a lower level and also show higher expression of proliferation 
genes than luminal A tumors.  The normal-like subtype contains breast tumors that cluster 
together with normal breast samples; this is thought to be due to mis-sampling of tumor 
tissue caused by contamination with too much normal mammary gland tissue.  
 
Molecular subtypes and outcome 
Molecular subtypes are predictive of clinical outcome with the Luminal A subtype 
having a generally more favorable outcome[3].  Individuals with HER2+/ER- and basal-like 
tumors generally have the worst outcomes.  Studies have also shown that these different 
molecular subtypes have distinct responses to therapy[7, 8].  The basal-like subtype has 
drawn a lot of attention because these patients generally have a poor outcome and unlike the 
other subtypes that have targeted therapies with measurable efficacies in current clinical use 
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(luminal A and B – tamoxifen and aromatase inhibitors, HER2+ - trastuzamab), the basal-
like subtype does not have any efficacious targeted therapy.  In addition, the breast cancer 
molecular subtypes have different patterns of metastasis.  In a recent study it was shown that 
brain-metastasizing breast cancer belongs predominantly to the basal-like and HER2+ 
subtypes[9], while Luminal A tumors tend to metastasize to the bone. 
 
Several recent studies have examined ductal carcinoma in situ (DCIS) lesions and 
determined that they display immunophenotypes analogous to the subtypes of invasive breast 
carcinomas [10-13].  Interestingly, basal-like DCIS was associated with unfavorable 
prognostic variables including high-grade nuclei, overexpression of p53 (an indication of p53 
mutation), and a high Ki-67 labeling index[12].  These studies show that potential precursor 
lesions can be identified that give rise to the breast cancer subtypes   The classifications of 
DCIS have important implications given the increased numbers of DCIS currently diagnosed 
with the use of mammography. 
 
Genetic changes and subtype 
Each breast cancer subtype has specific associated genetic changes (Table 1.1).  p53 
mutations have been shown to be common in basal-like, HER2+/ER-, and luminal B tumors, 
but infrequent in the luminal A subtype[3].  BRCA1 carriers have been shown to be 
predisposed to developing basal-like tumors[4]. Phosphatidylinositol 3-kinase, catalytic, α 
polypeptide (PIK3CA) mutations are frequent in the luminal A subtype (unpublished and 
[14]).  Recurrent copy number alterations have also been shown to differ between tumor 
subtypes[15, 16].  Basal-like tumors are relatively enriched for low-level copy number gains 
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and losses.  High-level DNA amplification on the other hand has been shown to be very 
frequent in luminal B tumors including the region on chromosome 8q containing the c-myc 
oncogene as well as 11q containing Cyclin D1.  As expected, HER2+ER- tumors have been 
shown to have high-level amplification of 17q harboring HER2/ERBB2.  Subtypes of breast 
cancer also show signature loss of heterozygosity (LOH) events[17].  X-chromosomal 
isodisomy, the loss of the inactive X and duplication of the active X, has been shown to be 
characteristic of basal-like tumors[18]. 
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Bold indicates changes found in both copy number studies. 
Table 
1.1 
 Alterations and risk factors associated with the molecular subtypes of 
breast cancer 
Alteration Luminal A Luminal B HER2+/ER- Basal-like References 
Familial     BRCA1 [4] 
Mutations 
   p53 
   PIK3CA 
 
few 
+++ 
 
+ 
++ 
 
++ 
+ 
 
+++ 
++ 
 
 
[3] 
unpublished 
 
Hormone 
receptors 
ER+, PR+, 
AR+ 
ER+, PR+, 
AR+ 
ER-, PR-, 
AR+ 
ER-, PR-, 
AR- 
 
Copy Number 
   Gains 
    
    
    
    
   Losses 
    
 
 
 
Amplifications 
 
 
 
    
 
Other 
 
1q, 16p 
 
 
 
 
16q 
 
 
 
 
8p11-12, 
11q13-14, 
12q13-14, 
17q11-12, 
17q21-24, 
20q13 
 
1p, 1q, 8q, 
17q, 20p, 
20q 
 
 
1p, 3p, 3q, 
8p, 13q, 
16q, 17p, 
22q 
 
6q, 7p, 
8p11-12, 
two regions 
8q, 9q, 
11q13-14, 
19q, 20q 
 
1q, 7p, 8q, 
16p, 20q 
 
 
 
1p, 8p, 13q, 
18q 
 
 
 
17q 
 
1q, 3q, 6q, 
7q, 8q, 10p, 
11p, 17q, 
21q 
 
3p, 4p, 4q, 
5q, 12q, 13q, 
14q, 15q 
 
 
 
 
 
 
 
 
X-
chromosomal 
isodisomy 
 
[15, 16] 
 
 
 
 
 
 
 
[18] 
Risk factors 
and 
associations 
old age, 
pregnancy 
protective 
old age, 
alcohol, 
HRT use 
 early age, 
early age at 
menarche, 
AA, high 
WHR, high 
BMI, 
pregnancy 
risk, 
pregnancy-
no lactation 
risk 
[19-21] 
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Breast cancer subtypes and risk factors 
In a recent study, the prevalence of breast cancer subtypes was shown to vary by 
race[19].  The basal-like breast cancer subtype was more prevalent among premenopausal 
African American women compared with postmenopausal African American women and 
non–African American women of any age in the Carolina breast cancer study.  The luminal 
A subtype, on the other hand, was less prevalent among premenopausal African American 
women.  Recently, it has been discovered that risk factors differ between the subtypes in 
large population based studies[20, 21].  In the Carolina Breast Cancer Study (CBCS), 
pregnancy was shown to be protective for luminal A tumors with increased parity, and 
younger age at first full-term pregnancy each showing a reduced risk.  A high waist-to-hip 
ratio increased the risk of luminal A tumors in postmenopausal women.  On the other hand, 
pregnancy was shown to be associated with basal-like breast cancer with parity and younger 
age at first full-term pregnancy increasing risk.  Women who did not breastfeed were also 
shown to have an increased risk of basal-like breast cancer showing that there are protective 
affects from lactation.  Abdominal adiposity was also associated with basal-like breast cancer 
in pre-and postmenopausal women in the CBCS study[20].  In the Polish Breast Cancer 
Study, increasing body mass index reduced the risk of luminal A tumors among 
premenopausal women[21].  Increasing age at menarche was associated with a reduced risk 
of basal-like breast cancer in this study.  Family history was a risk factor in all the subtypes, 
but had the greatest impact in the basal-like subtype.  These studies show that the subtypes 
display distinct risk factor profiles and not surprisingly, luminal A, the most common 
subtype, shows associations typically described for breast cancer as a whole.   
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Breast cancer has long been studied and treated as one disease.  The molecular 
profiling and epidemiological studies have shown that breast cancer should be considered as 
several distinct diseases that develop along a continuum of epithelial cell types in the 
mammary gland.  Molecular genetic and epidemiological studies of these subtypes show that 
each of these has different etiologies and patterns of progression.  This is important when 
considering preventative and therapeutic strategies.  Therefore, no one model should be 
expected to adequately represent breast cancer and studying multiple models representative 
of each molecular subtype would be of great benefit. 
 
The mouse as a model of human breast cancer 
Beginning with the first transgenic mouse mammary tumor model, the MMTV-Myc 
mouse[22], developed by Phil Leder and coworkers, researchers have spent the last three 
decades genetically engineering mouse models to study human breast cancer.  There are 
several advantages to using the mouse as a model including the ability to manipulate their 
genes and genomes, their short generation times, and small size.  They physiologically and 
molecularly resemble humans more than many other model organisms.  Like the human, the 
mouse genome is also fully sequenced.  Mouse models also provide an in vivo model system 
for the evaluation of different therapies.  Although xenograft models, human cancer cell lines 
grown in immunodeficient mice, have had limited success in predicting drug efficacy, early 
results with genetically engineered mice (GEM) have been promising [23].  Murine models 
also show some caveats including different mammary physiology and estrous cycle.  There 
are also indications that there is a difference in the capacity of primary cells to be 
transformed between the two species[24].  
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 In 1999 a panel of distinguished medical and veterinary pathologists with mammary 
gland expertise gathered in Annapolis, Maryland to develop a classification of breast lesions 
based on their examination of 39 GEM models[25].  One of the main conclusions of their 
consensus report was that overall GEMs give rise to tumors that histologically do not 
resemble the common types of human breast cancer.  To date, many studies have been 
performed where rodent models and human tumors are compared pathologically and 
phenotypically [26], however, it is still not clear how accurately most murine models mimic 
human tumors. With the advent of genomic profiling, a new tool for comparative genomics 
emerged offering a powerful means for cross species comparisons.  We hypothesized that 
some murine mammary models will better mimic specific human tumor subtypes than others.  
These similarities can be identified using genomic profiling. 
 
Mouse tumor models are created with genetic lesions seen in humans 
Murine mammary tumor models have shown us that genes associated with human 
breast cancer can induce cancer in mice.  Inactivation of p53, BRCA1, and Rb, and 
activation/overexpression of MYC and HER2 have been used to initiate tumorigenesis in the 
mouse mammary gland.  Models have been created through a multitude of approaches 
including the transgenic overexpression of genes involved in human cancer, the production 
of dominant negative proteins to disrupt protein function, the targeted disruption of tumor 
suppressor genes, and by mutagenesis through infection with the Mouse Mammary Tumor 
Virus (MMTV) or treatment with chemical agents (i.e. DMBA).  A number of different 
rodent gene promoters have been employed in order to achieve mammary specific 
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expression.  A majority of the transgenics generated have employed either the MMTV Long 
Terminal Repeat (MMTV-LTR) or the whey acidic protein (WAP) promoter.  The MMTV-
LTR is active in ductal and alveolar cells throughout mammary development and its 
transcriptional activity increases during pregnancy.  In contrast, the WAP promoter, which 
expresses preferentially in alveolar cells, is only active in the mid-pregnant and lactating 
mammary gland.  The C3(1) component of the rat prostate steroid binding protein has also 
been used to drive transgene expression in one of the mouse mammary cancer models.   A 
variety of other promoters have been used to drive expression in the mammary gland 
including H19, bovine β-lactoglobin, metallothionen, keratin 5, and keratin 14.  The choice 
of transgene and promoter are both critical to the successful creation of relevant animal 
models. 
 
We have chosen to use several models, most of which are commonly used and many 
of which are initiated by events seen in human breast cancer (Figure 1.1).  The models/genes 
that we used in our initial studies are c-MYC, HER2/Neu, p53, RB, BRCA1, WNT1, and 
INT3/Notch4.  The first gene of interest is the c-myc oncogene, which is amplified in 30% 
and overexpressed in almost 70% of human breast cancer. Models targeting the c-myc 
oncogene to the mammary gland of mice have been created using both the MMTV 
promoter[22] and the WAP promoter[27].  These models have been important in showing 
that the overexpression of the c-myc oncogene in the mammary gland can initiate 
tumorigenesis. 
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The second gene is HER2/ERBB2 (human name), that encodes a receptor tyrosine 
kinase belonging to the epidermal growth factor receptor (EGFR) family and that has been 
shown to be amplified in 15-30% of human breast cancers[28-31].  As described above, 
overexpression of this gene is associated with a specific human subtype (HER2+ subtype) 
that is ER-negative.  It should also be pointed out that a subset of human tumors of the ER-
positive luminal subtypes also highly express HER2, suggesting that HER2 tumorigenesis 
can occur in at least 2 distinct cell types.  MMTV has been used to drive expression of 
HER2, also called ERBB2 or Neu in the mouse mammary gland[32-34](see [35]for an 
extensive review).  These mice develop mammary adenocarcinomas that have been described 
as histologically and cytologically very similar to human ductal carcinoma-in situ 
(DCIS)[26].  Also, expression of the viral protein polyoma middle T-antigen (PyMT) using 
the MMTV promoter leads to mammary tumors that are similar to Neu driven cancers[36].  
Tumors from this model are said to resemble the common scirrhous carcinomas in 
humans[26], while papillary tumors produced from this model resemble the less common 
human papillary breast cancer[26]. Like Neu[37], the PyMT model has also been shown to 
activate the src and PI3 kinase pathways[38].  Interestingly, these mice also have a high 
incidence of metastasis to the lung, which is greater than that seen in the MMTV-Neu model. 
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Figure 1.1.  Molecular pathways involved in mouse models of human breast cancer.  Many of the murine 
models (red) mimic genetic alterations seen in human breast cancer including inactivation of p53, BRCA1, and 
Rb, and activation/overexpression of MYC and HER2.  
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The p53 tumor suppressor is the most commonly altered gene in human breast cancer.  
It has been found to be mutated in about 30-40% of all human breast tumors with, as 
described above, much higher frequency in the two ER negative subtypes[3]. Mutations in 
p53 are also responsible for Li-Fraumeni syndrome, a hereditary disease predisposing 
patients to a spectrum of tumor types including breast.  p53 plays an important role in 
protecting the genome from DNA damage via blocking the cell cycle in the G1 phase, such 
that the cell is able to repair genomic damage.  If the cell is beyond repair, p53 can induce 
apoptosis or senescence.   When p53 function is removed, aberrant cell growth continues 
unchecked and the cells become genomically unstable.  Mice homozygous or heterozygous 
for a mutant p53 allele have been shown to present with many different tumor types, but 
primarily lymphomas.  These mice rarely develop mammary tumors.  However, it has been 
shown that modifier genes present in the BALB/c genetic background shifted the spectrum of 
tumors in p53+/- animals to include a significant increase in mammary gland carcinomas 
with exposure to ionizing radiation decreasing the latency to tumor formation[39, 40].  
Modifier genes on the BALB/c background have recently been mapped[41]. 
 
The retinoblastoma 1 (pRb) gene was found to be nonfunctional in up to 25% of 
human breast cancers.  There is also evidence of frequent alterations of other members of the 
pRb pathway in human breast cancer including p16INK4a loss [42] and cyclin D1 
amplification or overexpression [43].  pRb plays an important role in cell cycle progression, 
when cells exit G0 or G1 and enter S phase.  In quiescent or early G1-phase cells, pRb is 
hypophosphorylated and associates with specific members of the E2F transcription factor 
family, converting them to active transcriptional repressors.  Cell cycle progression from G 
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to S phase occurs when complexes of D-type cyclins/CDK4/CDK6 phosphorylate pRb, 
thereby allowing E2Fs to direct transcription of S phase genes.  The expression of the early 
region of Simian virus 40 large and small T-antigen (SV40-T-Ag) has been targeted to the 
mouse mammary gland using both the C3(1) promoter and the WAP promoter with both 
models being highly transforming.  SV40-T-Ag induces transformation through the 
inactivation of p53 and the Rb family members.  In addition, expression of T121, a fragment 
of SV40 T antigen that binds to and inactivates Rb family members, using the WAP 
promoter, also leads to the formation of mammary adenocarcinomas.  In this model, 
heterozygosity for a p53 null allele was shown to significantly shorten tumor latency with 
most tumors undergoing a subsequent loss of the wild-type allele[44].  These models show 
that inducing the deficiency of both Rb family members and p53 can induce tumor formation 
in the mammary gland, which is also seen in the most aggressive human breast tumors. 
 
Mutations in BRCA1 have been identified as a hereditary cause of human breast 
cancer.  Tumors from carriers of BRCA1 mutations were shown to cluster with “basal-like” 
tumors[3, 45].  BRCA1 has not, however, been found to be somatically mutated in sporadic 
breast cancer, although methylation of BRCA1 is seen (infrequent in basal-like[46]).  
BRCA1 has been implicated in the regulation of DNA repair and gene transcription and in 
the maintenance of genome integrity.  Several mouse models have been generated to assess 
the functions of BRCA1 in the mammary gland.  Unlike humans, mice carrying a 
heterozygous mutation in this gene do not display a detectable increase in tumor formation.  
However, when combined with mutations in p53, an increase in mammary tumor incidence 
was observed[47].  In addition, in mice generated to carry a BRCA1-null allele in addition to 
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a conditional mutation of BRCA1 in mammary epithelial cells, tumor formation occurred 
after long latency[48].  Loss of p53 was shown to accelerate tumor formation in this model as 
well, which again mimics the human scenario where BRCA1 mutant tumors tend to be p53 
deficient. 
 
Tumors have been generated in mice infected with the mouse mammary tumor virus 
(MMTV) by insertional mutagenesis and activation of oncogenes.  The oncogenes affected 
include Int3 (Notch 4)[49] and Wnt1.  Mammary specific promoters have also been used to 
drive these transgenes resulting in lesions that resemble those induced by the virus. Acinar 
tumors of humans are rare but histologically resemble those from the Wnt1 transgene[26].  
There is no direct evidence of Notch 4 or Wnt1 being activated in human breast cancer, 
however, evidence of their involvement is emerging and includes the observed high 
expression of wnt pathway members in basal-like tumors in our current human data[50]. 
 
Research introduction 
Mouse models that mimic human disease can be useful for understanding the 
mechanisms of development and progression of disease.  They can also be useful for testing 
therapeutics and prevention strategies, but only if we understand what type of human disease 
each model represents.  The identification of accurate and useful models is therefore 
extremely important.  Historically, morphologic and architectural criteria have been used to 
categorize mammary tumors in mice.  More recently, the use of molecular markers by 
immunohistochemistry has added another dimension to the categorization of mammary 
tumors[51].  The goal of the work presented here was to use gene expression analysis by 
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microarray to classify mouse models of breast cancer and determine those models that 
accurately represent human subtypes.  Additionally, we have determined gene expression 
patterns representative of cell types of origin and oncogenic pathways that are seen in 
common between the two species that have helped inform us about the human disease.  
Overall, these gene expression profiles will be used to determine which mouse models are 
useful for particular genetic and pharmacologic studies.   
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CHAPTER II 
IDENTIFICATION OF CONSERVED GENE EXPRESSION FEATURES BETWEEN 
MURINE MAMMARY CARCINOMA MODELS AND HUMAN BREAST TUMORS 
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ABSTRACT 
Background 
Although numerous mouse models of breast carcinomas have been developed, we do 
not know the extent to which any faithfully represent clinically significant human 
phenotypes. To address this need, we characterized mammary tumor gene expression profiles 
from thirteen different murine models using DNA microarrays and compared the resulting 
data to that of human breast tumors.  
 
Results 
Unsupervised hierarchical clustering analysis showed that six models (TgWAP-Myc, 
TgMMTV-Neu, TgMMTV-PyMT, TgWAP-Int3, TgWAP-Tag, and TgC3(1)-Tag) yielded 
tumors with distinctive and homogeneous expression patterns within each strain. However, in 
each of four other models (TgWAP-T121, TgMMTV-Wnt1, Brca1Co/Co;TgMMTV-Cre;p53+/- 
and DMBA-induced), tumors with a variety of histologies and expression profiles developed. 
In many models, similarities to human breast tumors were recognized including proliferation 
and human breast tumor subtype signatures. Significantly, tumors of several models 
displayed characteristics of human basal-like breast tumors including two models with 
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induced Brca1 deficiencies. Tumors of other murine models shared features with human 
luminal tumors.  
 
Conclusions 
Many of the defining characteristics of human subtypes were conserved among 
mouse models. Although no single model recapitulated all the expression features of a given 
human subtype, these shared expression features provide a common framework for an 
improved integration of murine mammary tumor models with human breast tumors. 
 
BACKGROUND 
Global gene expression analyses of human breast cancers have identified at least three 
major tumor subtypes and a normal breast tissue group[1]. Two subtypes are ER-negative 
with poor patient outcomes[2, 3]; one of these two subtypes is defined by the high expression 
of HER2/ERBB2/NEU (HER2+/ER-) and the other shows characteristics of 
basal/myoepithelial cells (basal-like). The third major subtype is ER-positive and Keratin 
8/18-positive, and designated the “luminal” subtype. This subtype has been subdivided into 
good outcome “luminal A” tumors and poor outcome “luminal B” tumors[2, 3]. These 
studies emphasize that human breast cancers are multiple distinct diseases, with each of the 
major subtypes likely harboring different genetic alterations and responding distinctly to 
therapy[4, 5]. Further similar investigations may well identify additional subtypes useful in 
diagnosis and treatment, however, such research would be accelerated if the relevant disease 
properties could be accurately modeled in experimental animals. Signatures associated with 
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specific genetic lesions and biologies can be causally assigned in such models, potentially 
allowing for refinement of human data. 
 
 
Significant progress in the ability to genetically engineer mice has led to the 
generation of models that recapitulate many properties of human cancers[6]. Mouse 
mammary tumor models have been designed to emulate genetic alterations found in human 
breast cancers including inactivation of TP53, BRCA1, and RB, and overexpression of MYC 
and HER2/ERBB2/NEU. Such models have been generated through several strategies 
including transgenic overexpression of oncogenes, expression of dominant interfering 
proteins, targeted disruption of tumor suppressor genes, and by treatment with chemical 
carcinogens[7]. While there are many advantages to using the mouse as a surrogate, there are 
also potential caveats including differences in mammary physiologies and the possibility of 
unknown species-specific pathway differences. Furthermore, it is not always clear which 
features of a human cancer are most relevant for disease comparisons (e.g. genetic 
aberrations, histological features, tumor biology). Genomic profiling provides a tool for 
comparative cancer analysis and offers a powerful means of cross-species comparison. 
Recent studies applying microarray technology to human lung, liver, or prostate carcinomas 
and their respective murine counterparts have reported commonalities[8-10]. In general, each 
of these studies focused on a single or few mouse models. Here, we used gene expression 
analysis to classify a large set of mouse mammary tumor models and human breast tumors. 
The results provide biological insights among and across the mouse models, and comparisons 
with human data identify biologically and clinically significant shared features. 
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RESULTS 
Murine tumor analysis.  
To characterize the diversity of biological phenotypes present within murine 
mammary carcinoma models, we performed microarray-based gene expression analyses on 
tumors from 13 different murine models (Table 1) using Agilent microarrays and a common 
reference design[1]. We performed 122 microarrays consisting of 108 unique mammary 
tumors and 10 normal mammary gland samples. Using an unsupervised hierarchical cluster 
analysis of the data (Appendix IIA), murine tumor profiles indicated the presence of gene 
sets characteristic of endothelial cells, fibroblasts, adipocytes, lymphocytes, and two distinct 
epithelial cell types (basal/myoepithelial and luminal). Grouping of the murine tumors in this 
unsupervised cluster showed that some models developed tumors with consistent, model-
specific patterns of expression, while other models showed greater diversity and did not 
necessarily group together. Specifically, the TgWAP-Myc, TgMMTV-Neu, TgMMTV-
PyMT, TgWAP-Int3 (Notch4), TgWAP-Tag and TgC3(1)-Tag tumors had high within-model 
correlations. In contrast, tumors from the TgWAP-T121, TgMMTV-Wnt1, 
Brca1Co/Co;TgMMTV-Cre;p53+/-, and DMBA-induced models showed diverse expression 
patterns. The p53-/- transplant model tended to be homogenous with 4/5 tumors grouping 
together, while the Brca1+/-;p53+/- IR and p53+/- IR models showed somewhat heterogeneous 
features between tumors; yet, 6/7 Brca1+/-;p53+/- IR and 5/7 p53+/- IR were all present within 
a single dendrogram branch. 
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Table 2.1. Summary of mouse mammary tumor models. 
 
Tumor Model Number 
of 
Tumors 
Specificity 
of Lesions
Experimental 
Oncogenic 
Lesion(s) 
Strain Reference 
WAP-myc 13 WAP1 cMyc 
overexpression
FVB Sandgren et al., 
1995
WAP-Int3 7 WAP Notch4 
overexpression
FVB Gallahan et al., 
1996
WAP-T121 5 WAP pRb,p107,p130 
inactivation 
B6D2 Simin et al., 2004 
WAP-T121 2 WAP pRb,p107,p130 
inactivation 
BALB/cJ Simin et al., 2004 
WAP-Tag 5 WAP SV40 L-T (pRb, 
p107, p130, p53, 
p300 inactivation, 
others); SV40 s-t
C57Bl/6 Husler et al., 
1998 
C3(1)-Tag 8 C3(1) 2 SV40 L-T (pRb, 
p107, p130, p53, 
p300 inactivation, 
others); SV40 s-t
FVB Maroulakou et 
al., 1994 
MMTV-neu 10 MMTV3 Unactivated rat 
Her2 
i
FVB Guy et al., 1992 
MMTV-Wnt1 11 MMTV Wnt 1 
overexpression
FVB Tsukamoto et al., 
1988
MMTV-PyMT 7 MMTV Py-MT (activation 
of Src, PI-3’ 
kinase, and Shc)
FVB Guy et al., 1992 
MMTV-Cre;Brca1Co/Co; 
p53+/- 
10 MMTV Brca1 truncation 
mutant; p53 
heterozygous null 
C57Bl/6 Xu et al., 1999 
p53-/- transplanted 5 none p53 inactivation BALB/cJ Jerry et al., 2000 
Medroxyprogesterone-
DMBA-induced 
11 none Random DMBA-
induced 
FVB Yin et al., 2005 
p53+/- irradiated 7 none p53 heterozygous 
null, random IR 
i d d
BALB/cJ Backlund et al., 
2001 
Brca1+/-;p53+/- irradiated 7 none Brca1 and p53 
heterozygous null, 
random IR 
induced
BALB/cJ Cressman et al., 
1999 
 
1-whey acidic protein promoter, commonly restricted to lactating mammary gland luminal 
cells 
2-C3(1)- 5' flanking region of the C3(1) component of the rat prostate steroid binding protein 
(PSBP), expressed in mammary ductal cells.  
3-MMTV- mouse mammary tumor virus promoter, often expressed in virgin mammary gland 
epithelium, induced with lactation; often expressed at ectopic sites (e.g. Lymphoid cells, 
salivary gland, others) 
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Figure 2.1. Mouse models intrinsic gene set cluster analysis. (A) Overview of the 
complete 866 gene cluster diagram. (B) Experimental sample associated dendrogram colored 
to indicate 10 groups. (C) Luminal epithelial gene expression pattern that is highly expressed 
in TgMMTV-PyMT, TgMMTV-Neu, and TgWAP-myc tumors. (D) Genes encoding 
components of the basal lamina. (E) A second basal epithelial cluster of genes including 
Keratin 5. (F) Genes expressed in fibroblast cells and implicated in epithelial to 
mesenchymal transition including snail homolog 1. (G) A second mesenchymal cluster that is 
expressed in normals. See Additional data file 2 for the complete cluster diagram with all 
gene names.  
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As with previous human tumor studies[1, 3], we performed an “intrinsic” analysis to 
select genes consistently representative of groups/classes of murine samples. In the human 
studies, expression variation for each gene was determined using biological replicates from 
the same patient, and the “intrinsic genes” identified by the algorithm had relatively low 
variation within biological replicates and high variation across individuals. In contrast, in this 
mouse study we applied the algorithm to groups of murine samples defined by an empirically 
determined correlation threshold of > 0.65 using the dendrogram from Additional data file 2. 
This “intrinsic” analysis yielded 866 genes that we then used in a hierarchical cluster analysis 
(Figure 2.1). This analysis identified ten potential groups containing five or more samples 
each, including a normal mammary gland group (Group I) and nine tumor groups (designated 
Groups II-X). 
 
In general, these 10 groups were contained within four main categories that included 
(Figure 2.1B; left to right): A) the normal mammary gland samples (Group I) and tumors 
with mesenchymal characteristics (Group II), B) tumors with basal/myoepithelial features 
(Groups III-V), C) tumors with luminal characteristics (Groups VI-VIII), and D) tumors 
containing mixed characteristics (Groups IX, X). Group I contained all normal mammary 
gland samples, which showed a high level of similarity regardless of strain, and was 
characterized by the high expression of basal/myoepithelial (Figure 2.1E) and mesenchymal 
features including vimentin (Figure 2.1G). Group II samples were derived from several 
models (2/10 Brca1Co/Co;TgMMTV-Cre;p53+/-, 3/11 DMBA-induced, 1/5 p53-/- transplant, 
1/7 p53+/- IR, 1/10 TgMMTV-Neu and 1/7 TgWAP-T121) and also showed high expression of 
mesenchymal features (Figure 2.1G) that were shared with the normal samples in addition to 
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a second highly expressed mesenchymal-like cluster that contained snail homolog 1 (a gene 
implicated in epithelial-mesenchymal transition[11]), the later of which was not expressed in 
the normal samples (Figure 2.1F). Two TgWAP-Myc tumors at the extreme left of the 
dendrogram, which showed a distinct spindloid histology, also expressed these 
mesenchymal-like gene features. Further evidence for a mesenchymal phenotype for Group 
II tumors came from Keratin 8/18 (K8/18) and Smooth Muscle Actin (SMA) 
immunofluorescence (IF) analyses, which showed that most spindloid tumors were K8/18-
negative and SMA-positive (Figure 2.2L). 
 
The second large category contained Groups III-V, with Group III (4/11 DMBA-
induced and 5/11 Wnt1), Group IV (7/7 Brca1+/-;p53+/- IR, 4/10 Brca1Co/Co;TgMMTV-
Cre;p53+/-, 4/6 p53+/- IR and 3/11 Wnt1) and Group V (4/5 p53-/- transplant and 1/6 p53+/- IR), 
showing characteristics of basal/myoepithelial cells (Figure 2.1D and E). These features were 
encompassed within two expression patterns. One cluster included Keratin 14, 17 and LY6D 
(Figure 2.1D); Keratin 17 is a known human basal-like tumor marker[1, 12], while LY6D is a 
member of the Ly6 family of GPI-anchored proteins that is highly expressed in head & neck 
squamous cell carcinomas[13]. This cluster also contained components of the basement 
membrane (e.g . Laminins) and hemidesmosomes (e.g. Envoplakin and Desmoplakin), which 
link the basement membrane to cytoplasmic keratin filaments. A second basal/myoepithelial 
cluster highly expressed in Group III and IV tumors and a subset of DMBA tumors with 
squamous morphology, was characterized by high expression of ID4, TRIM29, and Keratin 5 
(Figure 2.1E), the latter of which is another human basal-like tumor marker[1, 12]. This gene 
set is expressed in a smaller subset of models compared to the set described above (Figure 
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2.1D), and is lower or absent in most Group V tumors. As predicted by gene expression data, 
most of these tumors stained positive for Keratin 5 (K5) by IF (Figure 2.2G-K). 
 
The third category of tumors (Groups VI-VIII) contained many of the “homogenous” 
models, all of which showed a potential “luminal” cell phenotype: Group VI contained the 
majority of the TgMMTV-Neu (9/10) and TgMMTV-PyMT (6/7) tumors, while Groups VII 
and VIII contained most of the TgWAP-Myc tumors (11/13) and TgWAP-Int3 samples (6/7), 
respectively. A distinguishing feature of these tumors (in particular Group VI) was the high 
expression of XBP1 (Figure 2.1C), which is a human luminal tumor-defining gene[14-17]. 
These tumors also expressed tight junction structural component genes including Occludin, 
Tight Junction Protein 2 and 3, and the luminal cell Keratins 8/18 (K8/18) (not shown). IF 
for K8/18 and K5 confirmed that these tumors all exclusively expressed K8/18 (Fig. 2.2B-F). 
 
Finally, Group IX (1/10 Brca1Co/Co;TgMMTV-Cre;p53+/-, 4/7 TgWAP-T121 tumors 
and 5/5 TgWAP-Tag tumors) and Group X (8/8 TgC3(1)-Tag) tumors were present at the far 
right and showed “mixed” characteristics; in particular, the Group IX tumors showed some 
expression of luminal (Figure 2.1C), basal (Figure 2.1D) and mesenchymal genes (Figure 
2.1F), while Group X tumors expressed basal (Figure 2.1E+F) and mesenchymal genes 
(Figure 2.1F+G).  
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Figure 2.2.  Immunofluorescence staining of mouse samples for basal/myoepithelial and 
luminal cytokeratins. (A) Wild type mammary gland stained for Keratins 8/18 (red) and 
Keratin 5 (green) shows K8/18 expression in luminal epithelial cells and K5 expression in 
basal/myoepithelial cells. (B-F) Mouse models that showed luminal-like gene expression 
patterns stained with K8/18 (red) and K5 (green). (G-K) Tumor samples that showed basal-
like, or mixed luminal and basal characteristics by gene expression, stained for K8/18 (red) 
and K5 (green). (J) A subset of Brca1Co/Co;TgMMTV-Cre;p53+/-  tumors showing nodules of 
K5/K8/18 double positive cells. (L) a splindloid tumor stained for K8/18 (red) and Smooth 
Muscle Actin (green). 
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Immunofluorescence analyses showed that, as in humans[12, 18], the murine basal-
like models tended to express K5 while the murine luminal models expressed only K8/18. 
However, some of the murine basal-like models developed tumors that harbored nests of 
cells of both basal (K5+) and luminal (K8/18+) cell lineages. For example, in some 
TgMMTV-Wnt1[19], DMBA-induced (Figure 2.2G, I), and Brca1-deficient strain tumors, 
distinct regions of single positive K5 and  K8/18 cells were observed within the same tumor. 
Intriguingly, in some Brca1Co/Co;TgMMTV-Cre;p53+/- samples, nodules of double-positive 
K5 and K8/18 cells were identified, suggestive of a potential transition state or 
precursor/stem cell population (Figure 2.2J), while in some TgMMTV-Wnt1 (Figure 2.2H) 
[19]and Brca1-deficient tumors, large regions of epithelioid cells were present that had little 
to no detectable K5 or K8/18 staining (data not shown). 
 
The reproducibility of these groups was evaluated using “Consensus Clustering 
(CC)”[20]. CC using the intrinsic gene list showed strong concordance with the results from 
Figure 2.1 and supports the existence of most of the groups identified using hierarchical 
clustering analysis (Appendix IIB). However, our further division of some of the CC-defined 
groups appears justified based upon biologic knowledge. For instance, hierarchical clustering 
separated the normal mammary gland samples (Group I) and the histologically distinct 
spindloid tumors (Group II), which were combined into a single group by CC. Groups VI 
(TgMMTV-Neu and PyMT) and VII (TgWAP-Myc) were likewise separated by hierarchical 
clustering, but CC placed them into a single category. CC was also performed using all genes 
that were expressed and varied in expression, which showed far less concordance with the 
intrinsic list based classifications, and which often separated tumors from individual models 
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into different groups (Appendix IIB C, bottom most panel); for example, the TgMMTV-Neu 
tumors were separated into 2-3 different groups, whereas these were distinct and single 
groups when analyzed using the intrinsic list. This is likely due to the presence or absence of 
gene expression patterns coming from other cell types (i.e. lymphocytes, fibroblasts, etc.) in 
the “all genes” list, which causes tumors to be grouped based upon qualities not coming from 
the tumor cells[1].  
 
Mouse-Human combined unsupervised analysis.  
The murine gene clusters were reminiscent of gene clusters identified previously in 
human breast tumor samples. To more directly evaluate these potential shared characteristics, 
we performed an integrated analysis of the mouse data presented here with an expanded 
version of our previously reported human breast tumor data. The human data were derived 
from 232 microarrays representing 184 primary breast tumors and 9 normal breast samples 
also assayed on Agilent microarrays and using a common reference strategy (combined 
human data sets of [21-23] plus 58 new patients/arrays). To combine the human and mouse 
data sets, we first used the Mouse Genome Informatics database to identify well-annotated 
mouse and human orthologous genes. We then performed a Distance Weighted 
Discrimination correction, which is a supervised analysis method that identifies systematic 
differences present between two data sets and makes a global correction to compensate for 
these global biases[24]. Finally, we created an unsupervised hierarchical cluster of the mouse 
and human combined data (Figure 2.3). 
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This analysis identified many shared features including clusters that resemble the 
cell-lineage clusters described above. Specifically, human basal-like tumors and murine 
Brca1+/-;p53+/-;IR, Brca1Co/Co;TgMMTV-Cre;p53+/-, TgMMTV-Wnt1, and some DMBA-
induced tumors were characterized by the high expression of Laminin gamma 2, Keratins 5, 
6B, 13, 14, 15, TRIM29, c-KIT and CRYAB (Figure 2.3B), the last of which is a human basal-
like tumor marker possibly involved in resistance to chemotherapy[25]. As described above, 
the Brca1+/-;p53+/-;IR, some Brca1Co/Co;TgMMTV-Cre;p53+/, DMBA-induced, and 
TgMMTV-Wnt1 tumors stained positive for K5 by IF, and human basal-like tumors tend to 
stain positive using a K5/6 antibody[1, 12, 18, 26], thus showing that basal-like tumors from 
both species share K5 protein expression as a distinguishing feature. 
 
The murine and human “luminal tumor” shared profile was not as similar as the 
shared basal profile, but did include the high expression of SPDEF, XBP1 and GATA3 
(Figure 2.3C), and both species luminal tumors also stained positive for K8/18 (Figure 2.2 
and see [18]). For many genes in this luminal cluster, however, the relative level of 
expression differed between the two species. For example, some genes were consistently 
high across both species’ tumors (e.g. XBP1, SPDEF and  GATA3), while others including 
TFF, SLC39A6, and FOXA1, were high in human luminal tumors and showed lower 
expression in murine tumors. Of note is that the human luminal epithelial gene cluster always 
contains the Estrogen-Receptor (ER) and many estrogen-regulated genes including TFF1 and 
SLC39A6[22]; since most murine mammary tumors, including those profiled here, are ER-
negative, the apparent lack of involvement of ER and most ER-regulated genes could explain  
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Figure 2.3. Unsupervised cluster analysis of the combined gene expression data for 232 
human breast tumor samples and 122 mouse mammary tumor samples. (A) A color-
coded matrix below the dendrogram identifies each sample; the first two rows show clinical 
ER and HER2 status respectively with red=positive, green=negative, and gray=not tested; the 
third row includes all human samples colored by intrinsic subtype as determined from 
Additional data file 6; red=basal-like, blue=luminal, pink= HER2+/ER-, yellow=claudin-low 
and green=normal breast-like. The remaining rows correspond to murine models indicated at 
the right. (B) A gene cluster containing basal epithelial genes. (C) A luminal epithelial gene 
cluster that includes XBP1 and GATA3. (D) A second luminal cluster containing Keratins 8 
and 18. (E) Proliferation gene cluster. (F) Interferon-regulated genes. (G) 
Fibroblast/mesenchymal enriched gene cluster. (H) The Kras2 amplicon cluster. See 
Additional data file 5 for the complete cluster diagram. 
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the difference in expression for some of the human luminal epithelial genes that show 
discordant expression in mice. 
 
Several other prominent and noteworthy features were also identified across species 
including a “proliferation” signature that includes the well documented proliferation marker 
Ki-67 (Figure 2.3E)[1, 27, 28] and an interferon-regulated pattern (Figure 2.3F)[27]. The 
proliferation signature was highest in human basal-like tumors and in the murine models with 
impaired pRb function (i.e. Group IX and X tumors). Currently, the growth regulatory impact 
of interferon-signaling in human breast tumors is not understood, and murine models that 
share this expression feature (TgMMTV-Neu, TgWAP-Tag, p53-/- transplants, and spindloid 
tumors) may provide a model for future studies of this pathway. A fibroblast profile (Figure 
2.3G) that was highly expressed in murine samples with spindloid morphology and in the 
TgWAP-Myc “spindloid” tumors  was also observed in many human luminal and basal-like 
tumors; however, on average, this profile was expressed at lower levels in the murine tumors, 
which is consistent with the relative epithelial to stromal cell proportions seen histologically. 
 
Through these analyses we also discovered a potential new human subtype (Figure 
2.3, top line-yellow group). This subtype that was apparent in both the human only and 
mouse-human combined data set, is referred to as the “claudin-low” subtype and is 
characterized by the low expression of genes involved in tight junctions and cell-cell 
adhesion including Claudins 3,4, 7, Occludin, and E-cadherin (Figure 2.3D). These human 
tumors (n=13) also showed low expression of luminal genes, inconsistent basal gene 
expression, and high expression of lymphocyte and endothelial cell markers. All but one 
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tumor in this group was clinically ER-negative, and all were diagnosed as Grade II or III 
infiltrating ductal carcinomas (Appendix IIC for representative H&E images); thus, these 
tumors do not appear to be lobular carcinomas as might be predicted by their low expression 
of E-cadherin. The uniqueness of this group was supported by shared mesenchymal 
expression features with the murine spindloid tumors (Figure 2.3G), which cluster near these 
human tumors and also lack expression of the Claudin gene cluster (Figure 2.3D). Further 
analyses will be required to determine the cellular origins of these human tumors. 
 
A common region of amplification across species  
The murine C3(1)-Tag tumors and a subset of human basal-like tumors showed high 
expression of a cluster of genes including Kras2, Ipo8, Ppfibp1, Surb, and Cmas that are all 
located in a syntenic region corresponding to human chromosome 12p12 and mouse 
chromosome 6 (Figure 2.3H). Kras2 amplification is associated with tumor progression in 
the C3(1)-Tag model[29], and haplo-insufficiency of Kras2 delays tumor progression[30]. 
High co-expression of Kras2-linked genes prompted us to test whether DNA copy number 
changes might also account for the high expression of Kras2 among a subset of the human 
tumors. Indeed, 9 of 16 human basal-like tumors tested by qPCR had increased genomic 
DNA copy numbers at the KRAS2 locus; however, no mutations were detected in KRAS2 in 
any of these 16 basal-like tumors. In addition, Van Beers et al. reported that this region of 
human Chromosome 12 is amplified in 47% of BRCA1-associated tumors by comparative 
genomic hybridization (CGH) analysis[31]; BRCA1-associated tumors are known to exhibit a 
basal-like molecular profile[3, 32]. In cultured human mammary epithelial cells (HMEC), 
which show basal/myoepithelial characteristics[1, 33], both high oncogenic H-ras and SV40 
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Large T-antigen expression are necessary for transformation[34]. Taken together, these 
findings suggest that amplification of KRAS2 may either influence the cellular phenotype or 
define a susceptible target cell type for basal-like tumors. 
 
Mouse-Human shared intrinsic features.  
To simultaneously classify mouse and human tumors, we identified the gene set that 
was in common between a human breast tumor intrinsic list (1300 genes described in Hu et 
al.[21] ) and the mouse intrinsic list developed here (866 genes). The overlap of these two 
lists totaled 106 genes, which when used in a hierarchical clustering analysis (Figure 2.4) 
identifies four main groups: the leftmost group contained all the human basal-like, “claudin-
low”, and 5/44 HER2+/ER- tumors, and the murine C3(1)-Tag, TgWAP-Tag, and spindloid 
tumors. The second group (left to right) contained the normal samples from both humans and 
mice, a small subset of human 6/44 HER2+/ER- and 10/92 luminal tumors, and a significant 
portion of the remaining murine basal-like models. By clinical criteria, nearly all human 
tumors in these two groups were clinically classified as ER-negative.  
 
The third group contained 33/44 human HER2+/ER- tumors and the murine 
TgMMTV-Neu, MMTV-PyMT and TgWAP-Myc samples. Although the human HER2+/ER- 
tumors are predominantly ER-negative, this comparative genomic analysis and their keratin 
expression profiles as assessed by IHC, suggests that the HER2+/ER- human tumors are 
“luminal” in origin as opposed to showing basal-like features[18]. The fourth and right-most 
group was composed of ER-positive human luminal tumors and lastly, the mouse TgWAP- 
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Figure 2.4. Cluster analysis of mouse and human tumors using the subset of genes 
common to both species intrinsic lists (106 total genes). (A) Experimental sample 
associated dendrogram color coded according to human tumor subtype and with a matrix 
below showing murine tumor origins. (B) The complete 106 gene cluster diagram. (C) Close-
up of genes known to be important for human basal-like tumors. (D) Close-up of genes 
known to be important for human luminal tumors including ER. (E) Expression pattern of 
HER2/ERBB2/NEU. 
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Int3 (Notch4) tumors were in a group by themselves. This data shows that although many 
mouse and human tumors were located on a large dendrogram branch that contained most 
murine luminal models and human HER2+/ER- tumors, none of the murine models we tested 
showed a strong human “luminal ” phenotype that is characterized by the high expression of 
ER, GATA3, XBP1 and FOXA1. These analyses suggest that the murine luminal models like 
MMTV-Neu, showed their own unique profile that was a relatively weak human luminal 
phenotype that is missing the ER-signature. Presented at the bottom of Figure 2.4 are 
biologically important genes discussed here, genes previously shown to be human basal-like 
tumor markers (Figure 2.4C), human luminal tumor markers including ER (Figure 2.4D), and 
HER2/ERBB2/NEU (Figure 2.4E). 
 
A comparison of gene sets defining human tumors and murine models.  
We used a second analysis method called Gene Set Enrichment Analysis 
(GSEA)[35], to search for shared relationships between human tumor subtypes and murine 
models. For this analysis, we first performed a two-class unpaired Significance Analysis of 
Microarray (SAM)[36] analysis for each of the ten murine groups defined in Figure 2.1, and 
obtained a list of highly expressed genes that defined each group. Next, we performed similar 
analyses using each human subtype versus all other human tumors. Lastly, the murine lists 
were compared to each human subtype list using GSEA, which utilizes both gene list overlap 
and gene rank (Table 2.2). We found that the murine Groups IX (p=0.004) and X (p=0.001), 
which were comprised of tumors from pRb-deficient/p53-deficient models, shared significant 
overlap with the human basal-like subtype and tended to be anti-correlated with human 
luminal tumors (p=0.083 and 0.006 respectively). Group III murine tumors (TgMMTV-Wnt1 
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mostly) significantly overlapped human normal breast samples (p=0.008), possibly due to the 
expression of both luminal and basal/myoepithelial gene clusters in both groups. Group IV 
(Brca1-deficient and Wnt1) showed a significant association (p=0.058) with the human basal-
like profile. The murine Group VI (TgMMTV-Neu and TgMMTV-PyMT) showed a near 
significant association (p=0.078) with the human luminal profile and were anti-correlated 
with the human basal-like subtype (p=0.04). Finally, the murine Group II spindloid tumors 
showed significant overlap with human “claudin-low” tumors (p=0.001), which further 
suggests that this may be a distinct and novel human tumor subtype.  
 
We also performed a two-class unpaired SAM analysis using each mouse model as a 
representative of a pathway perturbation using the transgenic “event” as a means of defining 
groups. Models that yielded a significant gene list (FDR = 1%) were compared to each 
human subtype as described above (Appendix IID). The models based upon SV40 T-antigen 
(all C3(1)-Tag and WAP-Tag tumors) shared significant overlap with the human basal-like 
tumors (p=0.002) and were marginally anti-correlated with the human luminal class. The 
BRCA1 deficient models (all Brca1+/-;p53+/- IR and Brca1Co/Co;TgMMTV-Cre;p53+/- tumors) 
were marginally significant with human basal-like tumors (p=0.088). The TgMMTV-Neu 
tumors were nominally significant (before correction for multiple comparisons) with human 
luminal tumors (p=0.006) and anti-correlated with human basal-like tumors (p=0.027). 
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Table 2,2. Gene Set Enrichment Analysis (GSEA) of the 10 murine groups versus 5 
human subtypes. Statistically significant findings are highlighted in bold. 
Is Class 
    BASAL-like LUMINAL HER2+/ER- NORMAL claudin-LOW 
Mouse 
Class 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
I 1882 - - 0.4625 0.8755 0.5388 0.9137 0.1659 0.5628 0.0048 0.1028 
II 912 - - - - 0.5867 0.9609 - - 0.0021 0.001 
III 143 0.5289 0.9048 - - 0.5285 0.9047 0 0.008 - - 
IV 1019 0 0.0581 - - - - - - - - 
V 34 - - 0.8492 0.998 0.9324 0.999 - - 0.0427 0.09274 
VI 820 - - 0.0062 0.0783 0.3536 0.7864 0.8653 0.9769 - - 
VII 851 0.1258 0.3768 - - 0.5616 0.9137 - - - - 
VIII 236 0.1449 0.6098 0.3483 0.8205 - - 0.01878 0.2349 - - 
IX 462 0.0019 0.004 - - 0.56 0.9509 - - - - 
X 338 0 0.001 - - 0.9275 0.998 - - - - 
            
            
Is Not Class 
    BASAL-like LUMINAL HER2+/ER- NORMAL claudin-LOW 
Mouse 
Class 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
I 1882 0.0128 0.1662 - - - - - - - - 
II 912 0.3996 0.8348 0.8601 0.999 - - 0.3602 0.7655 - - 
III 143 - - 0.3178 0.7259 - - - - 0.7628 0.991 
IV 1019 - - 0.1833 0.6516 0.398 0.8427 0.2241 0.7255 0.1453 0.6116 
V 34 0.86 1 - - - - 0.0656 0.1653 - - 
VI 820 0 0.04 - - - - - - 0.1043 0.4444 
VII 851 - - 0.1733 0.5151 - - 0.5403 0.9128 0.1628 0.5215 
VIII 236 - - - - 0.1131 0.5305 - - 0.6427 0.961 
IX 462 - - 0.04305 0.0833 - - 0.022 0.037 0.2612 0.5936 
X 338 - - 0.02236 0.0682 - - 0.1313 0.3717 0.5437 0.9489 
 
 
The two most important human breast tumor biomarkers are ER and HER2, therefore, 
we also analyzed these data relative to these two markers. Of the 232 human tumors assayed 
here, 137 had ER and HER2 data assessed by IHC and microarray data. As has been noted 
before[3, 18, 21], there is a very high correlation between tumor intrinsic subtype and ER and 
HER2 clinical status (p<0.0001): for example, 81% of ER+ tumors were of the luminal 
phenotype, 63% of HER2+ tumors were classified as HER2+/ER-, and 80% of ER- and 
HER2- tumors were of the Basal-like subtype. Using GSEA, we compared the 10 mouse 
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classes as defined in Figure 2.1 (Appendix IIE) and the mouse models based gene lists 
(Appendix IIF) to the human data/gene lists that were obtained by performing supervised 
analyses based upon human ER and HER2 status (please note that analyses using HER2 
status alone (i.e. HER2+ vs. HER2-), and ER+ and  HER2+ vs. others were not included as 
human classes because HER2 status alone only yielded genes on the HER2 amplicon, and the 
ER+ and HER2+ classification did not yield a significant gene list). We found that the 
murine Groups IX (p=0.009) and X (p=0.003) tumors shared significant overlap with ER- 
HER2- human tumors and were significantly anti-correlated with human ER+ tumors 
(p=0.024 and 0.043 respectively). Group VI murine samples (TgMMTV-Neu and TgMMTV-
PyMT) likewise showed the same trend of enrichment with ER+ human tumors and anti-
correlation with the ER- HER2- class. Although not perfect, these GSEA results are 
consistent with our observations from Figures 2.1 and 2.3 and again demonstrate that the 
basal-like profile is robustly shared between humans and mice, while the luminal profile 
shows some shared and some distinct features across species. 
 
DISCUSSION 
Gene expression profiling of murine tumors and their comparison to human tumors identified 
characteristics relevant to individual murine models, to murine models in general, and to 
cancers of both species. First was the discovery that some murine models developed highly 
similar tumors within models, while others showed heterogeneity in expression and 
histological phenotypes. For the homogenous models, the study of progression or response to 
therapy is simplified because confounding variation across individuals is low. An example of 
this consistency even extended to secondary events that occurred within the TgC3(1)-Tag 
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model, where many tumors shared the amplification and high expression of Kras2 (Figure 
2.3H) - a feature also evident in a subset of human basal-like tumors. 
 
In contrast to the “homogenous” models are models such as TgWAP-T121, DMBA-
induced and Brca1Co/Co;TgMMTV-Cre;p53+/-, where individual tumors within a given model 
often showed different gene expression profiles and histologies. It is likely that these models 
fall into one of three scenarios that could explain their heterogeneity: the first represented by 
the TgWAP-T121 model[37], is that the transgene is responsible only for initiating 
tumorigenesis, leaving progression events to evolve stochastically and with longer latency 
periods. Such a model would likely give rise to different tumor subtypes depending on the 
subsequent pathways that are disrupted during tumor progression. A second possibility is that 
the initiating event generates genomic instability such that multiple distinct pathways can be 
affected by the experimental causal event, which may be the mechanism in the Brca1-
inactivation tumors. The third scenario is that the target cell of transformation is a multi-
potent progenitor with the ability to undergo differentiation into multiple epithelial lineages, 
or even mesenchymal lineages (e.g. DMBA-induced and Brca1Co/Co;TgMMTV-Cre;p53+/-); 
support for this hypothesis comes from Keratin IF analyses in which, even within a 
histologically homogenous tumor, two types of epithelial cells are present (Figures 2.2G-K). 
The presence of subsets of individual cells positive for markers of two epithelial cell types 
also supports this possibility (Figure 2.2J). Alternative hypotheses include the possibility that 
multiple cell types sustain transforming events, and also that extensive non-cell-autonomous 
tissue responses occur. Regardless of the paradigm of transformation for these heterogeneous 
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models, the study of progression or therapeutic response will best be accomplished by first 
sub-setting by subtype, and then focusing on biological phenotypes.  
 
There are at least two major applications for genomic comparisons between human 
tumors and their potential murine counterparts. First, such studies should identify those 
models that contain individual and/or global characteristics of a particular class of human 
tumors. Examples of important global characteristics identified here include the classification 
of murine and human tumors into basal and luminal groups. It appears as if four murine 
models developed potential luminal-like tumors (TgMMTV-Neu, TgMMTV-PyMT, 
TgWAP-Myc, and TgWAP-Int3), which is not surprising since both MMTV and WAP are 
thought to direct expression in differentiated alveolar/luminal cells[38, 39]; however, it 
should be noted that the luminal profile across species was not statistically significant likely 
due to the lack of ER and ER-regulated genes in the murine luminal tumors. Several murine 
models did show expression features consistent with human basal-like tumors including the 
TgC3(1)-Tag, TgWAP-Tag and Brca1-deficient models. The SV40 T-antigen used in the 
TgC3(1)-Tag and TgWAP-Tag models inactivates p53 and RB, which also appear to be two 
likely events that occur in human basal-like tumors because these tumors are known to 
harbor p53 mutations[2], have high mitotic grade and the highest expression of proliferation 
genes (Figure 2.3 [2, 3]), which are known E2F targets[40]. The proliferation signature in 
human breast cancers, is itself prognostic[41], and is also predictive of response to 
chemotherapy[42]. These data suggest that human basal-like tumors might have impairment 
of RB function and highlight an important shared feature of murine and human mammary 
carcinomas.  
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The finding that Brca1 loss (coincident with p53 mutation), in mice gives rise to 
tumors with a basal-like phenotype is notable because humans carrying BRCA1 germline 
mutations also develop basal-like tumors[3, 32], and most human BRCA1 mutant tumors are 
p53-deficient[43, 44]. These data suggest a conserved predisposition of the basal-like cell 
type, or its progenitor cell, to transform as a result of BRCA1, TP53, and RB-pathway loss. 
Most DMBA-induced carcinomas also showed basal-like cell lineage features, suggesting 
that this cell type is also susceptible to DMBA-mediated tumorigenesis. Finally, some 
TgMMTV-Wnt1 tumors showed a combination of basal-like and luminal characteristics by 
gene expression, which is consistent with the observation that tumors of this model generally 
contain cells from both mammary epithelial lineages[45]. 
 
The second major purpose of comparative studies is to determine the extent to which 
analyses of murine models can inform the human disease and guide further discovery. An 
example of murine models informing the human disease is encompassed by the analysis of 
the new potential human subtype discovered here (i.e. claudin-low subtype). Further analysis 
will be necessary to confirm whether this is a bona fide subtype, however, the statistically 
significant gene overlap with a histologically distinct subset of murine tumors suggests it is a 
distinct biological entity. A second example of the murine tumors guiding discovery in 
humans was the common association of a K-Ras containing amplicon in a subset of human 
basal-like tumors and in the murine basal-like TgC3(1)-Tag strain tumors.  
 
An important caveat to all comparative studies is that there are clear biological 
differences between mice and humans, which may or may not directly impact disease 
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mechanisms. A potential example of inherent species difference could be the aforementioned 
biology associated with ER and its downstream pathway. In humans, ER is highly expressed 
in luminal tumors[1], with the luminal phenotype being characterized by the high expression 
of some genes that are ER-regulated like PR and RERG[22], and other luminal genes that are 
likely GATA3-regulated including AGR2 and K8/18[46]. In mice, ER expression is low to 
absent in all the tumors we tested, as is the expression of most human ER-responsive genes. 
This finding is consistent with previous reports that most late-stage murine mammary tumors 
are ER-negative ([47] and references within). However, it should be noted that two human 
luminal tumor-defining genes (XBP1 and GATA3[46], were both highly expressed in murine 
luminal tumors (Additional data file 2). Taken together, these data suggest that the human 
“luminal” profile may actually be a combination of at least two profiles, one of which is ER-
regulated and another of which is GATA3-regulated; support for a link between GATA3 and 
luminal cell origins comes from GATA3 loss studies in mice where the selective loss of 
GATA3 in the mammary gland resulted in either a lack of luminal cells, or a significant 
decrease in the number and/or maturation of luminal cells[48, 49]. These results suggest that 
in the mouse models tested here, the ER-regulated gene cassette that is present in human 
luminal tumors is missing, and that the GATA3-mediated luminal signature remains. Due to 
the partial luminal tumor signature in mice, we believe that the murine luminal models 
including TgMMTV-Neu profiled here best resemble human luminal tumors and more 
specifically possibly luminal B tumors, which are luminal tumors that express low amounts 
of ER and show a poor outcome[2, 3, 21]. While human HER2+/ER- subtype tumors and the 
murine TgMMTV-Neu, TgMMTV-PyMT, and TgWAP-Myc fall loosely next to each other 
in the intrinsic-shared cluster (Figure 2.4), all of the other data argues against this 
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association.  A few murine ER-positive mammary tumor models have been developed[50-
53], however, none of these models were analyzed here. 
 
Of note, many expression patterns detected in this study were only observed in one 
species or the other, and it is possible that some of these differences may arise from technical 
limitations rather than reflect important biological differences. Comparison between two 
expression datasets, especially when derived from different species, remains a technical 
challenge. Thus, we acknowledge the possibility that artifacts may have been introduced 
depending on the data analysis methodology. However, we are confident that the analyses 
described here identified many common and biologically relevant clusters including a 
proliferation, basal epithelial, interferon-regulated and fibroblast signature, thus showing that 
the act of data combining across species did retain important features present within the 
individual data sets. These analyses also confirm the notion that there is not a single murine 
model that perfectly represents a human breast cancer subtype, however, the murine models 
do show shared features with specific human subtypes and it is these commonalties that will 
lay the groundwork for many future studies. 
 
MATERIALS AND METHODS 
Murine and human tumors.  
The murine tumor samples were obtained from multiple participating investigators, 
who all maintained the mice and harvested the murine tumors in the 0.5-1cm stage following 
internationally recognized guidelines. The details concerning strain background, promoter, 
transgene, and specific alleles, etc., are provided in Additional data file 1. All human tumor 
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samples were collected from fresh frozen primary breast tumors using IRB-approved 
protocols and were profiled as described in[21-23]. The clinical and pathological information 
for these human samples can be obtained at  https://genome.unc.edu/pubsup/breastTumor/. 
 
Microarray Experiments.  
Total RNA was collected from murine tumors, and wild type mammary samples of 
both FVB and BALB/c inbred strains. RNA was purified using the Qiagen RNeasy Mini Kit 
according to the manufacturer’s protocol using 20-30 mg tissue. RNA integrity was assessed 
using the RNA 6000 Nano LabChip kit followed by analysis using a Bioanalyzer (Agilent). 
Two micrograms of total RNA was reverse transcribed, amplified and labeled with Cy5 using 
a Low RNA Input Amplification kit (Agilent). The common reference RNA sample for these 
experiments consisted of total RNA harvested from equal numbers of C57Bl6/J and 129 male 
and female Day1 pups (a gift from Dr. Cam Patterson, UNC). The Reference RNA was 
reverse transcribed, amplified, and labeled with Cy3. The amplified sample and reference 
were co-hybridized overnight to Agilent Mouse Oligo Microarrays (G4121A). They were 
then washed and scanned on an Axon GenePix 4000B scanner, analyzed using GenePix 4.1 
software and uploaded into our database where a Lowess normalization is automatically 
performed. 
 
Microarray Data Analysis.  
All primary microarray data is available from the University of North Carolina 
Microarray Database (UMD)[54], and at the Gene Expression Omnibus under the series 
GSE3165 (mouse and new human data), GSE1992, GSE2740 and GSE2741 (previously 
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published human data). The genes for all analyses were filtered by requiring the Lowess 
normalized intensity values in both channels to be > 30. The log2 ratio of Cy5/Cy3 was then 
reported for each gene.  In the final dataset, only genes that reported values in 70% or more 
of the samples were included. The genes were median centered and then hierarchical 
clustering was performed using Cluster v2.12[55]. For the murine unsupervised analysis, and 
human-mouse unsupervised cluster analyses, we filtered for genes that varied at least 3 fold 
or more, in at least 3 or more samples. Average linkage clustering was performed on genes 
and arrays and cluster viewing and display was performed using JavaTreeview v1.0.8[56]. 
 
Mouse Intrinsic gene set analysis.  
Intrinsic “groups” of experimental samples were chosen based upon having a Pearson 
correlation value of 0.65 or greater from the unsupervised clustering analysis of the 122 
murine samples. The analysis was performed using the Intrinsic Gene Identifier v1.0 by Max 
Diehn/Stanford University[1]. Technical replicates were removed from the file and the 
members of every highly correlated node were given identical class numbers, giving every 
sample that fell outside the 0.65 correlation cut off a class of their own. Using these criteria, 
16 groups of samples were identified (see Additional data file 1 for these groups) and a list of 
866 “intrinsic” genes was selected using the criteria of one standard deviation below the 
mean intrinsic gene value. A human intrinsic list of 1300 genes was created using a subset of 
146 of the 232 samples used here, and is described in Hu et al. 2005[21]. 
 
Consensus Clustering.  
Consensus Clustering[20] was performed locally using Gene Pattern 1.3.1 (Built Jan 
6, 2005), which was downloaded from the Broad Institute distribution site[57]. Analyses 
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were performed on the mouse dataset with all genes, and just with intrinsic genes separately. 
Ranges for the number of K clusters (or the focused number of classes) were from 2 to 15 to 
evaluate a wide range of possible groups. Using a Euclidian distance measure with average 
linkage, we re-sampled 1000 times with both column and row normalization.  
 
Combining murine and human expression data sets.  
Orthologous genes were reported by Mouse Genome Informatics (MGI 3.1) of The 
Jackson Laboratory. For both the human and murine datasets, Locus Link IDs assigned to 
Agilent oligo probe ID numbers were used to assign to MGI ID numbers. In cases where a 
single gene was represented by multiple probes, the median value of the redundant probes 
was used. This led to a total orthologous pairings of 14,680 Agilent probes.  Prior to 
combining the two datasets, each was column standardized to N(0,1), row median centered, 
and probe identifiers were converted to MGI IDs. The intersection of mouse and human MGI 
identifiers from genes that passed filters (same as used above) in both datasets yielded 7907 
orthologous genes in the total combined dataset. This data set was next corrected for 
systemic biases using Distance Weighted Discrimination[24]. Finally, the combined data set 
was used for an average linkage hierarchical clustering analysis. 
 
Gene Set Enrichment Analysis.  
We took the 232 human samples and classified them as Basal-like, Luminal, 
HER2+/ER-, claudin-low, and Normal Breast-like according to a clustering analysis of the 
human data set only (not shown), using the new Intrinsic/UNC human gene list developed in 
Hu et al.[21]. Second, the murine samples were also classified based upon their clustering 
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pattern in Figure 2.1 that used the mouse intrinsic gene list, and were assigned to Groups I-X. 
Two-class unpaired Significance Analysis of Microarrays analysis was performed for each 
murine class separately versus all other classes using an FDR of 1%[36], resulting in 10 
class-specific gene lists. Using only the set of highly expressed genes that were associated 
with each analysis (and ignoring the genes whose low expression correlated with a given 
class), GSEA[35]was performed in R (v. 2.0.1) using the GSEA R package[58]. The 10 
murine gene sets were then compared to each human subtype-ranked gene sets and 
significant enrichments reported. For statistical strength of these enrichments, GSEA uses 
Family Wise Error Rate (FWER) to correct for multiple testing and False Discovery Rate to 
reduce false positive reporting. The parameters used for all GSEA were: nperm = 1000, 
weighted.score.type = 1, nom.p.val.threshold = -1, fwer.p.val.threshold = -1, 
fdr.q.val.threshold = 0.25, topgs = 12, adjust.FDR.q.val = FALSE, gs.size.threshold.min = 
25, gs.size.threshold.max = 2000, reverse.sign = FALSE, preproc.type = 0, random.seed = 
3338, perm.type = 0, fraction = 1, replace = FALSE. 
 
Immunofluorescence .  
Paraffin-embedded sections (5 µm thick) were processed using standard 
immunostaining methods. The antibodies and their dilution were α-cytokeratin 5 (K5, 
1:8000, Covance, PRB-160P), α-cytokeratins 8/18 (Ker8/18, 1:450 Progen, GP11),. Briefly, 
slides were deparaffinized and hydrated through a series of xylenes and graded ethanol steps. 
Heat-mediated epitope retrieval was performed in boiling citrate buffer (pH 6.0) for 15 min., 
then samples cooled to room temperature for 30 min. Secondary antibodies for 
immunofluorescence were conjugated with  Alexa Fluor-488 or -594 fluorophores (1:200, 
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Molecular Probes, Invitrogen, Carlsbad, CA). IF samples were mounted with VectaShield 
Hardset with DAPI mounting media (Vector, Burlingame, CA).  
 
Human KRAS2 amplification assay.  
We performed real-time quantitative PCR and fluorescent melting curve analyses 
using genomic DNAs from 16 Basal-like tumors, a normal breast tissue samples, 2 leukocyte 
DNA, and 3 luminal tumors. DNA was extracted using the DNAeasy kit (Qiagen) and 
amplification was performed on the LightCycler using the following temperature parameters: 
95ºC, 8m; 50 cycles of 57ºC, 6s; 72ºC, 6s; 95ºC, 2s; followed by cooling to 60ºC and a 
0.1ºC/s ramp to 97ºC. Each PCR reaction contained 7.5ng template DNA in a 10µL reaction 
using the LightCycler Faststart DNA Master SYBR Green I kit (Roche). Relative DNA copy 
number for each gene was determined by importing an external efficiency curve and using a 
“normal” breast sample for a within-run calibrator. For each sample, the copy number for 
KRAS2 was divided by the average copy number of ACTB and G1P3. Amplification in any 
tumor was called if the relative fold change was greater than 3 standard deviations above the 
average of 5 control samples (2 normal leukocyte samples and 3 luminal tumors). 
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CHAPTER III 
FURTHER MOLECULAR PROFILING OF MOUSE MAMMARY TUMOR MODELS 
 
ABSTRACT  
We previously compared the expression profiles among 13 mouse mammary tumor 
models and compared them to the human intrinsic molecular subtypes of breast cancer.  This 
study has been continued and we now present data corresponding to more than 20 mouse 
models.  In our original study we did not include any ER+ models because unlike human 
breast cancers and rat carcinogen-induced mammary tumors, ER+ mammary tumors are 
uncommon in the mouse.  We have now profiled several ER+ models and in our analysis, 
these models do not mimic human ER+ luminal subtype tumors and do not highly express 
ER target genes.  Many of these models belong to a newly identified mouse molecular 
subtype with alveolar expression features.  A previously derived gene expression signature of 
p53 function shows high expression in mouse models with perturbed p53 further validating 
this gene set and the use of these models.  Finally, we find that tumors that arise in the mouse 
mammary gland due to haploinsufficiency for Brg1 span across most mouse tumor types 
indicating that Brg1 may have a possible role in the mammary gland stem or progenitor cell 
function.
INTRODUCTION 
Genetic engineering of mice to study mammary biology is now in its third decade.  
Well over 100 transgenes, targeted mutations, and compound models (combinations of 
transgenes and combinations of transgenes and targeted mutations) with increasing 
complexity have been used to study mammary tumorigenesis in mice.  We recently reported 
the comparison between 13 mouse mammary tumor models and 200 human breast tumors 
using gene expression profiling[1].  We showed that although no single mouse model 
recapitulated all the expression features of a given human subtype, many of the defining 
characteristics of the human subtypes were conserved among the mouse models.  Here we 
report a continuation of these profiling efforts using 10 additional murine tumor models.    
 
ER-alpha (ESR1) expression is one of the most common features of human breast 
cancers with ~70% of tumors reported to be positive.  Strikingly, mouse mammary models 
are almost entirely ER-negative in contrast to chemically induced rats which show nearly 
100% positivity.  In our original study, mouse models known to be ER+ were not included, 
however, now we have profiled several ER+ models: these include TgMMTV-AIB1 in which 
amplified in breast cancer 1, an estrogen receptor coactivator, is overexpressed under the 
MMTV promoter[2].  TgWap-Cre; Tel-NTRK3 mice conditionally express the Tel(Etv6)-
NTRK3 fusion oncoprotein, a translocation characteristic of secretory breast cancer (SBC), a 
rare form of breast cancer.  TgWap-Cre; p53flox/flox mice develop predominantly ER-
positive mammary tumors[3].  p18-/- mice on the BALBc genetic background develop 
mammary tumors with a relatively long latency and have been described as ER+.  When this 
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model is crossed to BRCA1+/- mice to generate p18-/-; BRCA1+/- mice, the latency 
decreases and the tumors have been reported to be predominantly ER-negative.  In addition, 
some TgMMTV-Wnt1 tumors have been reported to be ER-alpha positive[4].  Surprisingly, 
in our analysis, all of these ER+ murine models do not seem to closely mimic human ER+ 
luminal tumors.  Many of these models instead belong to a newly identified mouse molecular 
subtype with alveolar expression features and this murine subtype does not appear to have a 
clear human counterpart.  A previously derived gene expression signature of p53 function 
shows high expression in mouse models with perturbed p53 further validating this gene set 
and the use of these models[5].  We also find that tumors that arise in the mouse mammary 
gland due to haploinsufficiency for Brg1 span across most mouse tumor expression subtypes 
indicating that Brg1 may have a possible role in the mammary gland stem or progenitor 
cell[6].
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Table 3.1. Summary of mouse mammary tumor models. 
 
Tumor Model Tumor 
number 
Promoter Transgene/Gene 
knockout 
Strain Reference 
WAP-myc 20 WAP Myc overexpression FVB [7] 
WAP-Int3 7 WAP Notch4 overexpression FVB [8] 
WAP-T121 5 WAP pRb,p107,p130 
inactivation 
B6D2 [9] 
WAP-T121 2 WAP pRb,p107,p130 
inactivation 
BALB/cJ [9] 
WAP-Tag 5 WAP SV40 L-T (pRb, p107, 
p130, p53, p300 
inactivation, others); 
SV40 s-t
C57Bl/6 [10] 
C3(1)-Tag 16 C3(1)  SV40 L-T (pRb, p107, 
p130, p53, p300 
inactivation, others); 
SV40 s-t
FVB [11] 
MMTV-neu 18 MMTV Unactivated rat Her2 
overexpression 
FVB [12] 
MMTV-Wnt1 15 MMTV Wnt 1 overexpression FVB [13] 
MMTV-PyMT 7 MMTV PyMT (activation of Src, 
PI-3’ kinase, and Shc) 
FVB [14] 
MMTV-Cre;Brca1Co/Co; 
p53+/- 
10 MMTV Brca1 truncation mutant; 
p53 heterozygous null 
C57Bl/6 [15] 
p53-/- transplanted 5 none p53 inactivation BALB/cJ [16] 
Medroxyprogesterone-
DMBA-induced 
11 none Random DMBA-induced FVB [17] 
p53+/- irradiated 7 none p53 heterozygous null, 
random IR induced 
BALB/cJ [18] 
Brca1+/-;p53+/- irradiated 7 none Brca1 and p53 
heterozygous null, 
random IR induced 
BALB/cJ [19] 
MMTV-Fgf3  5 MMTV Fgf3/int2 overexpression FVB [20, 21] 
MMTV-DN89β-catenin 4 MMTV Overexpression of 
activated β-catenin 
FVB [22] 
WAP-Cre; p53flox/flox 4 WAP p53 inactivation C57Bl/6 
129  
[3] 
p53-/- spontaneous 5 none p53 inactivation BALB/cJ [23] 
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p18-/- 5 none p18 inactivation BALB/cJ unpublished 
p18-/-; Brca1+/- 12 none p18 inactivation BALB/cJ unpublished 
MMTV-AIB1 9 MMTV AIB1 overexpression FVB [2] 
WAP-Cre; Tel-NTRK3 12 WAP Tel-NTRK3 fusion 
protein expressed from 
endogenous Tel 1 locus 
mixed unpublished 
Brg1+/- 12 none Brg1heterozygous null mixed [6] 
MMTV-HRAS 8 MMTV Overexpression of 
activated HRAS 
FVB [24] 
 
Tumor models in bold are new to this study. 
 
 
 
RESULTS 
Previous intrinsic groups are retained 
We included the previously published 122 microarrays consisting of 13 tumor models 
and normal mammary glands from BALB/c and FVB/N mice and added an additional 113 
microarrays.  This additional set included 10 new models and 3 normal mammary glands 
from C57BL6 mice (Table 3.1).  We performed a new “intrinsic” analysis to select genes 
consistently representative of groups/classes of murine samples. As in the previous analysis, 
we applied the algorithm to groups of murine samples defined by an empirically determined 
correlation threshold of > 0.65 using the unsupervised cluster dendrogram. This “intrinsic” 
analysis yielded 1802 genes that we then used in a hierarchical cluster analysis (Figure 3.1). 
This analysis again identified the same nine tumor groups (II-X) from the first analysis as 
well as the normal mammary gland group (Group I).  There were an additional two large 
tumor groups which we designated groups XI and XII.  Group I contained all the normal 
mammary gland samples including the newly added C57BL6 samples.  This cluster also now 
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included some tumors in the outer branches (1/5 p18-/-, 2/5 TgMMTV-Fgf3, 1/18 TgMMTV-
Neu). Normal tissue contamination is most likely responsible for the clustering of tumor 
samples in this group. 
 
Group II samples generally have a spindloid morphology and show high expression 
of mesenchymal genes (previously shown).  These were derived from several models (2/10 
Brca1Co/Co;TgMMTV-Cre;p53+/-, 3/11 DMBA-induced, 1/5 p53-/- transplant, 1/7 p53+/- IR, 
1/18 TgMMTV-Neu and 1/7 TgWAP-T121).  New to this cluster was a single p53-/- 
spontaneous tumor (1/5), a TgMMTV- AIB1 tumor (1/9), and a tumor from a Brg1+/- mouse 
(1/12). 
 
Group III contains 2/11 DMBA-induced and 9/16 TgMMTV- Wnt1.  Interestingly, 
Group III now also contains all 4 TgMMTV-DN89β-catenin tumors and a TgMMTV-Fgf3 
tumor (1/5).  Two other TgMMTV-Fgf3 tumors are clustered just outside this group.  β-
catenin is a key downstream mediator of the wnt signaling pathway and mammary tumors 
from β-catenin transgenic mice have been shown to histologically resemble TgMMTV-Wnt1 
tumors[25, 26].   Fgf3, interestingly, has been shown to cooperate with Wnt1 during 
mammary tumorigenesis[20, 27]. 
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Figure 3.1 Intrinsic clustering of mouse mammary tumor models. The dendrogram is 
colored to indicate 12 groups. (A) Cluster of basal genes including Keratin 5. (B) A second 
basal epithelial cluster of genes including Keratin 14 and 17.   (C) XBP1 luminal epithelial 
gene expression cluster. (D) squamous gene cluster.  (E)  alveolar gene expression cluster.  
(F) A cluster containing Sca-1/Ly-6A and other Ly-6 family members. 
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Group IV contains 7/7 Brca1+/-;p53+/- IR, 4/10 Brca1Co/Co;TgMMTV-Cre;p53+/-, 4/7 p53+/- 
IR, 2/11 DMBA-induced, and 5/16 TgMMTV- Wnt1.    New to this data set, this cluster now 
includes 1/4 TgWap-Cre; p53flox/flox tumor, 2/12 Brg1+/- tumors, and all 5  
p53-/-  spontaneous tumors.  As we previously reported, Groups III and IV are characterized 
by the expression of a gene cluster that includes Keratin 5, P-cadherin, and ID4 (Figure 
3.1A).  They also show high expression of a Keratin 14, Keratin 17, and Ly-6D cluster 
although not as uniformly (Figure 3.1B).  Group V, as before, contains 4/5 p53-/- transplant 
tumors and a single p53+/- IR tumor (1/7).  Why these tumors, arising from p53-/- 
preneoplastic epithelium transplanted into the cleared mammary fat pad of syngeneic 
animals, cluster separately from the p53-/- tumors arising spontaneously is not known and 
likely merits further investigation.   
 
Table 3.2    Group III and IV Wnt1 tumors exhibit a difference in tumor latency. 
Tumor Transgene DOB 
Date of 
Necropsy Age (mo) 
Array 
tumor type 
Breeding 
Status 
CA02-467A Wnt1 1/23/2002 3/21/2002 1.9 Group IV Virgin 
CA02-478A Wnt1 12/9/2001 5/9/2002 5.0 Group III Virgin 
CA02-486A Wnt1 1/25/2002 6/13/2002 4.6 Group III Virgin 
CA02-493A Wnt1 1/22/2002 6/20/2002 5.0 Group III Virgin 
CA02-506A Wnt1 10/15/2001 4/18/2002 6.2 Group III Virgin 
CA02-570A Wnt1 N/A 12/6/2002 N/A 
no group 
(luminal) Virgin 
CA02-570B Wnt1 N/A 12/6/2002 N/A Group IV Virgin 
CA03-587A Wnt1 9/10/2002 2/5/2003 4.9 Group III Virgin 
CA03-613A Wnt1 N/A 4/23/2003 N/A Group III Virgin 
CA03-634A Wnt1 8/25/2003 1/6/2004 4.5 Group III Virgin 
CA04-676A Wnt1 2/9/2004 4/22/2004 2.4 Group IV Virgin 
CA04-683A Wnt1 3/2/2004 6/3/2004 3.1 Group IV N/A 
 
Interestingly, as reported previously, tumors from the TgMMTV- Wnt1 model were 
split almost exclusively into these two groups (Groups III and IV).  Examining the latency 
data we have available for a subset of these tumors coming from one institution, it was 
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apparent that there was a latency difference between Wnt1 tumors in the two groups with the 
Group III Wnt1 tumors (N=6) showing latencies of 4.5-6.2 months and the Group IV tumors 
(N=3) between 1.9-3.1 months (Table 3.2).  Furthermore, tumors in the two groups appear to 
have histological differences with tumors in Group IV showing a distinct radiating 
architecture (Figure 3.2).  One key expression difference between the two classes of Wnt1 
tumors is that the Group III Wnt1 tumors have a low expression of the XBP1 luminal gene 
cluster (Figure 3.1C).  Tumors that arise from crosses between TgMMTV- Wnt1 and 
TgMMTV-Neu or p53+/- cluster almost exclusively in Group IV (data not shown).  Further 
studies using the Wnt1 mice now in our colony are warranted to validate these results. 
 
 
Figure 3.2  Group III and IV Wnt1 tumors show distinct histologies.  Group IV Wnt1 
tumors (A,B) show a distinct radiating pattern with terminal end buds in the periphery and 
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ducts in the center different from Group III Wnt1 tumors (C,D).  Pictures courtesy of Igor 
Mikaelian. 
 
  
 
Group VI contains 16/18 TgMMTV-Neu tumors and 7/9 TgMMTV-PyMT tumors.  In 
addition, this cluster now contains 2/12 Brg1+/- tumors and 5/8 mammary tumors arising in 
TgMMTV-HRAS mice.  TgMMTV-HRAS tumors have been shown previously to be similar 
to TgMMTV-Neu and TgMMTV-PyMT both histologically and by gene expression[26, 28].  
These tumors are characterized by the high expression of the previously reported luminal 
XBP1 cluster (Figure 3.1C).  Groups VII and VIII again contained most of the TgWAP-Myc 
tumors (18/20) and TgWAP-Int3 samples (6/7), respectively. Group IX contains 1/7 
TgWAP-T121 tumors and all TgWAP-Tag tumors and Group X contains all 16 TgC3(1)-Tag 
tumors.  These two groups show the highest expression of proliferation genes (previously 
reported) and high expression of the Keratin 14 gene cluster (Figure 3.1B).  
 
Our previous analysis included a few samples described as showing extensive 
squamous differentiation.  In the previous report, however, we did not refer to this as a group 
because of the small number of samples contained.  This group now contains 8 tumors, 
which we labeled Group XI.  These samples include 4/11 DMBA-induced tumors, 2/12 
Brg1+/- tumors, and 2/12 p18-/-; BRCA1+/- tumors.  In addition to the high expression of the 
Keratin 5 and Keratin 14 clusters (Figure 3.1A,B), these tumors show very high expression 
of a cluster of genes that includes many genes involved in squamous differentiation (Figure 
3.1D).  Cornifelin is part of the insoluble cornified cell envelope of stratified squamous 
epithelia and Small proline-rich proteins are precursor proteins for the crosslinked envelope 
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formation in cells undergoing squamous differentiation. The expanded cluster also contains 
many other keratin genes. 
 
A new subtype of mouse mammary tumor 
Group XII is a new cluster containing a large number of the newly included 
samples/models, many of them reported to be ER-positive.  This cluster contains 4/5 p18-/- 
tumors, 10/12 p18-/- BRCA1+/- tumors, 4/9 TgMMTV-AIB1 tumors, 10/12 TgWAP-Cre; Tel-
NTRK3 tumors, 3/7 TgWAP-T121 and 3/12 Brg1+/- tumors.  Interestingly, common to this 
group was expression of a large cluster of genes including milk proteins, casein-alpha and 
gamma (Figure 3.1E), whey acidic protein, and MUC1 (not shown).  These tumors also 
highly express the murine hematopoetic stem cell antigen, Sca-1/Ly-6A and other Ly-6 
family members (Figure 3.1F).  These tumors also express the luminal XBP1 cluster at lower 
levels than Group VI.  This group is also heterogeneous with most of the TgWAP-Cre; Tel-
NTRK3 tumors and some of the p18-/- BRCA1+/- tumors expressing the Keratin 5 gene cluster 
(Figure 3.1A).  A number of the tumors in this group including most of the TgWAP-Cre; Tel-
NTRK3 also express the Keratin 14 gene cluster (Figure 3.1B).  Unlike Group VI, Group XII 
tumors did not show high expression of GATA-3, however, they highly express another 
GATA family member, GATA-2 (not shown).  It is interesting to speculate that GATA-2 
may have a similar role in alveolar cell fate and differentiation as GATA-3 has been shown 
to have in ductal luminal cells. 
 
Brg1+/- mice give rise to tumors that span across most tumor types 
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Brg1 tumors were found throughout the intrinsic cluster with at least one of these 
tumors being found in 5 of the 11 tumor groups including the new group with alveolar 
features (i.e. Group XII).  We speculate that Brg1 haploinsufficiency perturbs a mammary 
gland stem or multipotent progenitor in such a way that the secondary genetic changes that 
occur then committed the cells into the various subtypes. 
 
 
 
p53 signature  
We previously developed a p53 gene signature by comparing human cell line 
signatures of p53 loss with p53-mutation associated genes from human breast tumors[5].  
Here, we used the murine orthologs of these genes and averaged their expression to 
investigate the importance of the human p53 signature in our murine models (Figure 3.3).  
Strikingly, the “p53 up” signature appears to be higher in most murine tumors with deficient 
p53 function including both T-antigen models and at the same time the “p53 down” signature 
is low.  Interestingly, many of the TgWAP-Myc tumors also show this signature.  No studies 
looking for p53 mutations in this model have been published.  Whether this observation is a 
function of p53 pathway inactivation or cross-talk with Myc remains to be determined. 
 
Mouse mammary tumors do not highly express the ER response signature 
Similar to our approach with the p53 signature, we used a previously developed 
estrogen regulated gene signature that was developed by comparing the response of MCF-7 
to 17-beta estradiol filtered through ER+ human breast tumors[29].  We used the murine 
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orthologs of these genes and again averaged their expression.  Not many, if any, of the mouse 
tumors appear to highly express these genes.  With the exception of a single Wnt1 tumor 
(613A), the normal mammary glands seemed to have higher expression than the tumors.  
This seems to indicate that murine tumors do not express the 
ER-regulated genes we see in human tumors.  Further methods 
need to be used to validate this finding. 
                                                                                                                 
  
 
Figure 3.3 Pathway analysis in mouse models of breast 
cancer.  The samples are clustered by the intrinsic gene list as 
in Figure 3.1.  The previously developed p53 and ER response 
genes were separated into up and down genes were 
standardized, median centered, and the profile was averaged 
for each experimental sample. 
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Mouse-human comparison 
 As we had done in the previous report, we compared gene lists derived from the 
mouse classes with the human subtypes using Gene Set Enrichment Analysis (GSEA) with 
similar results (Table 3.3).  We again found that the murine Groups IX (p=0.006) and X 
(p=0.001), which were comprised of tumors from T-antigen initiated models, shared 
significant overlap with the human basal-like subtype. The murine Group VI (TgMMTV-
Neu, TgMMTV-PyMT, and TgMMTV-HRAS) showed a now significant association 
(p=0.04) with the human luminal profile. The murine Group II spindloid tumors showed 
significant overlap with claudin-low tumors (p=0.001).  Group XII (alveolar group) did not 
show significant gene enrichment with any of the human tumor subtypes.  It was the closest 
with the HER2+/ER- subtype (NOM p=0.02, FWER p=0.25). 
 
Table 3.3 Gene Set Enrichment Analysis (GSEA) of the 11 murine groups versus 5 human subtypes.  
Significant values are in bold.  Group V was not analyzed because a SAM FDR of 1% resulted in no significant 
genes. 
 
 Basal Luminal HER2 Claudin-low Normal 
Group  Size NOM 
p-value 
FWER 
p-value 
NOM p-
value 
FWER 
p-
value 
NOM 
p-
value 
FWER 
p-
value 
NOM p-
value 
FWER 
p-value 
NOM p-
value 
FWER 
p-value 
I 1313 - - 0.213 0.654 0.638 0.969 0.018 0.111 0.251 0.666 
II 724 - - - - 0.714 0.996 0.002 0.001 - - 
III 457 - - - - 0.433 0.893 - - 0.002 0.059 
IV 790 0.015 0.218 - - - - - - 0.322 0.815 
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VI 1411 - - 0.002 0.04 0.51 0.919 - - - - 
VII 1036 0.029 0.103 - - - - - - - - 
VIII 112 0.072 0.429 - - - - 0.156 0.586 0.066 0.359 
IX 156 0.006 0.006 - - - - - - - - 
X 665 0 0.001 - - - - 0.75 0.996 - - 
XI 209 0.773 0.997 - - 0.289 0.72 0.015 0.059 - - 
XII 527 - - 0.579 0.94 0.016 0.258 - - - - 
 
 
 
 
 NOT Basal NOT Luminal NOT HER2 NOT Claudin-low NOT Normal 
Group  Size NOM 
p-value 
FWER 
p-value 
NOM p-
value 
FWER 
p-
value 
NOM 
p-
value 
FWER 
p-
value 
NOM p-
value 
FWER 
p-value 
NOM p-
value 
FWER 
p-value 
I 1313 0.006 0.029 - - - - - - - - 
II 724 0.426 0.895 0.915 0.999 - - - - 0.435 0.914 
III 457 0.661 0.975 0.654 0.973 - - 0.859 0.999 - - 
IV 790 - - 0.282 0.785 0.419 0.883 0.372 0.877 - - 
VI 1411 0 0.043 - - - - 0.067 0.371 0.998 0.215 
VII 1036 - - 0.13 0.438 0.621 0.977 0.286 0.787 0.37 0.835 
VIII 112 - - 0.203 0.659 0.11 0.48 - - - - 
IX 156 - - 0.106 0.161 0.889 1 - - 0.111 0.148 
X 665 - - 0.01 0.047 0.65 0.981 - - 0.096 0.307 
XI 209 - - 0.438 0.887 - - - - 0.225 - 
XII 527 0.508 0.938 - - - - 0.044 0.303 0.314 0.83 
 
 
DISCUSSION 
ER-alpha expression is one of the most common features of human breast cancers 
with ~70% of tumors reported to be positive.  Mouse models, on the other hand, are almost 
entirely ER-negative.  In our original study, mouse models known to be ER+ were not 
included.  We have now profiled several ER+ models.  None of these models showed high 
expression of a previously published ER-response signature, however, additional analyses are 
needed to confirm the significance of this negative finding.  Many of these tumors are, 
however, part of a new mouse mammary tumor subtype with an alveolar phenotype.   
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The p53 tumor suppressor is the most commonly altered gene in human breast cancer.  
It has been found to be mutated in about 30-40% of all human breast tumors with much 
higher frequency in the two ER negative subtypes[30].  p53 plays an important role in 
protecting the genome from DNA damage via blocking the cell cycle in the G1 phase, such 
that the cell is able to repair genomic damage.  If the cell is beyond repair, p53 can induce 
apoptosis or senescence.   When p53 function is removed, aberrant cell growth continues 
unchecked and the cells become genomically unstable.  In a large number of the mouse 
models we have included in our study, p53 is perturbed, sometimes it is the initiating event 
(p53-/- transplant or spontaneous and p53+/-; IR) and others it is in combination with other 
initiators (Brca1Co/Co;TgMMTV-Cre;p53+/-, Brca1+/-; p53+/-; IR, TgC3(1)-Tag, TgWAP-Tag). 
We applied a previously published p53 gene signature, which was predictive of p53 mutation 
status and outcome in human breast tumors, to query the mouse models in our data set.  The 
majority of the tumors with perturbed p53 showed high expression of the average of this 
“p53 up” signature and low expression of the “p53 down” signature.  This further validates 
this signature and it also validates these mouse models as mimicking p53 loss seen in human 
breast tumors.   
 
As we continue adding new murine models to this data set we learn more about their 
biology and how they relate to one another and to human breast cancer.  Our comparison of 
mouse models has begun to hint at the cell types of origin of these tumors, some of which 
seem to have potential human correlates, while others do not.  Studying the cellular origins of 
cancers, whether the result of transformation of a stem cell, progenitor cell, or de-
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differentiation of a mature cell, is a challenging task in human model systems and therefore is 
a major strength to be taken advantage of in mouse models.   
 
MATERIALS AND METHODS 
Mouse tumor models 
Frozen tumors or total RNA was provided from the mouse models new to this study from the 
following investigators: MMTV-Fgf3 (Katrina Podsypanina and Harold Varmus - 
MSKCC)[20], MMTV-DN89β-catenin (Pam Cowin – NYU)[22], WAP-Cre; p53flox/flox 
(Eva Lee – UC Irvine)[3], p53-/- spontaneous (Daniel Medina – BCM)[23], p18-/- and p18-/-; 
Brca1+/- (Yue Xiong – UNC), MMTV-AIB1 (Myles Brown – DFCI)[2], WAP-Cre; Tel-
NTRK3 (Zhi Li and Stuart Orkin – Children’s Hospital Boston), Brg1+/-  (Scott Bultman and 
Terry Magnussen – UNC)[6], MMTV-HRAS (Yi Li – BCM and Katrina Podsypanina and 
Harold Varmus – MSKCC)[24]. 
  
RNA preparation 
Total RNA was collected from mouse mammary tumors or wild type mammary glands and 
purified using the Qiagen RNeasy Mini Kit according to the manufacturer’s protocol using 
20-30 mg tissue. RNA integrity was assessed using the RNA 6000 Nano LabChip kit 
followed by analysis using a Bioanalyzer (Agilent).  
 
Microarray Experiments. 
2.5 micrograms of total RNA was reverse transcribed, amplified and labeled with Cy5 using 
a Low RNA Input Amplification kit (Agilent). The reference RNA was reverse transcribed, 
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amplified, and labeled with Cy3. The amplified experimental sample and reference were 
combined and hybridized overnight to Agilent Mouse Oligo Microarrays (G4121A or B). 
They were then washed and scanned on an Axon GenePix 4000B scanner, analyzed using 
GenePix 4.1 software and uploaded into our database where a Lowess normalization is 
performed. 
 
Microarray Data Analysis 
This study included the 122 microarrays  previously published and available from the 
University of North Carolina Microarray Database (UMD and at the Gene Expression 
Omnibus under the series GSE3165.  We also added an additional 113 microarrays.  The 
genes for all analyses were filtered by requiring the Lowess normalized intensity values in 
both channels to be > 30. The log2 ratio of Cy5/Cy3 was then reported for each gene.  In the 
final dataset, only genes that reported values in 70% or more of the samples were included. 
The genes were median centered and then hierarchical clustering was performed using 
Cluster v2.12.  JavaTreeview v1.0.8 was used for cluster viewing and display.  We derived a 
new intrinsic gene list as we had done before.  Intrinsic “groups” were chosen based upon 
experimental samples having a Pearson correlation value of 0.65 or greater from the 
unsupervised clustering analysis of the expanded set of 235 murine samples. The analysis 
was performed using the Intrinsic Gene Identifier v1.0 developed by Max Diehn/Stanford 
University. Technical replicates were removed from the file and the members of every highly 
correlated node were given identical class numbers.  Every sample that fell outside the 0.65 
correlation cut off was given a class of their own. A list of 1802 “intrinsic” genes was 
selected using the criteria of one standard deviation below the mean intrinsic gene value. 
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Pathway Analysis 
Two gene signatures were obtained, an ER regulated gene signature[29] and a 52 gene p53 
inactivation signature [5].  Murine orthlogs were found for these genes and the data 
extracted.  Separate lists were used for the up and down genes and the genes were 
standardized, median centered, and the profile was averaged for each sample. 
 
Gene Set Enrichment Analysis.  
The murine samples were classified based upon their clustering pattern in Figure 3.1 that 
used the new mouse intrinsic gene list, and were assigned to Groups I-XII. Two-class 
unpaired Significance Analysis of Microarrays analysis was performed for each murine class 
separately versus all other classes using an FDR of 1%.  Group V did not return a gene list at 
FDR of 1% and therefore, we were left 11 class-specific gene lists. Using only the set of 
highly expressed genes that were associated with each analysis (and ignoring the genes 
whose low expression correlated with a given class), GSEA was performed using GSEA in 
R. The 11 murine gene sets were then compared to each human subtype-ranked gene sets and 
significant enrichments reported. For statistical strength of these enrichments, GSEA uses 
Family Wise Error Rate (FWER) to correct for multiple testing and False Discovery Rate to 
reduce false positive reporting.  
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CHAPTER IV 
PHENOTYPIC EVALUATION OF A NEW MOLECULAR SUBTYPE OF HUMAN 
INVASIVE BREAST CARCINOMA 
 
ABSTRACT 
Global gene expression profiling of human breast cancers has identified five distinct 
and prevalent subtypes of tumors (luminal A, luminal B, normal breast-like, HER2+/ER-, 
and basal-like). As a result of continuing these microarray studies we have identified a new 
and relatively infrequent (3-5%) human subtype that was not apparent in smaller datasets. 
This subtype, referred to as “Claudin-low”, is defined by the low expression of genes 
involved in tight junctions and cell-cell adhesion including Claudins 3 and 12, Occludin, and 
E-cadherin. These tumors also show a marked increased expression of lymphocyte markers, a 
low expression of luminal genes, inconsistent basal gene expression, and high expression of 
endothelial cell markers. The aim of this study was to characterize the histologic and 
immunophenotypic properties of “Claudin-low” tumors that were first positively identified 
using DNA microarray analysis. Detailed histologic review and immunohistochemistry for 
Claudin 3 and E-cadherin was performed on tumors with known microarray profiles 
including 19 “Claudin-low” tumors. Most of these tumors were described as high grade 
ductal carcinomas with marked stromal desmoplasia. Several “Claudin-low” tumors showed 
 
increased tumor infiltrating lymphocytes and most were ER- and HER2-negative.  
Consistent with their transcriptional profiles, immunohistochemical analysis showed that 
most claudin-low tumors expressed Claudin 3 and E-cadherin at low levels. 
 
 
INTRODUCTION 
Five distinct and prevalent subtypes of human breast tumors (luminal A, luminal B, 
normal breast-like, HER2+/ER-, and basal-like) have been identified using expression 
profiling[1-3].  As a result of continuing these microarray studies with larger patient sets, it is 
anticipated that there will be further stratification of these subtypes in addition to uncovering 
new molecular subtypes that were not appreciated before because of their infrequent 
occurrence.  We believe we have identified a new and relatively rare (3-5%) human subtype 
that was not apparent in smaller datasets[4]. This subtype, referred to as “Claudin-low”, is 
defined by a gene expression pattern that includes low levels of genes involved in tight 
junctions and cell-cell adhesion including Claudins 3 and 12, Occludin, and E-cadherin. 
These tumors show a marked increased expression of B cell and T cell markers. These 
tumors also showed low expression of luminal epithelial genes. The aim of this study was to 
characterize the histologic and immunophenotypic properties of “Claudin-low” tumors that 
were first positively identified using DNA microarray analysis. Detailed histologic review 
was performed on tumors with known microarray profiles including 19 “Claudin-low” 
tumors and immunohistochemistry for Claudin 3 and E-cadherin was performed.  
 
 
 
RESULTS 
A new intrinsic subtype shows low expression of tight junction and cell-cell adhesion 
associated genes 
We clustered a breast cancer dataset generated at UNC, containing 482 microarrays 
consisting of 349 primary breast tumor samples, 3 breast tumor xenografts, and 18 normal 
breast samples assayed on Agilent microarrays using the previously published intrinsic gene 
set[1] (Figure 4.1).  As before, this clustering separated the samples into distinct subtypes 
(luminal A+B combined, normal breast-like, HER2+/ER-, basal-like, and basal/HER2).  This 
clustering also revealed an additional subtype which shows low expression of a cluster of 
genes including the tight junction and cell-cell adhesion associated genes Claudin 3, 
Occludin, and E-cadherin.  We therefore referred to this new subtype as Claudin-low.  
Claudin-low tumors were also low for the expression of luminal tumor defining genes and 
inconsistent in expression for the basal-like gene cluster.
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Figure 4.1. Hierchical clustering of breast tumors using intrinsic gene list.  The 
dendrogram is colored to represent the intrinsic subtypes; luminal=blue, HER2/ER-=pink, 
normal-like=green, basal-like=red, basal/HER2=purple and the claudin-low subtype=yellow. 
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Morphological and clinical features of Claudin-low tumors 
We performed a detailed histological review of the Claudin-low tumors (Figure 4.2 
and Appendix IIC).  These tumors predominantly included high grade ductal carcinomas that 
were associated with marked stromal desmoplasia, which is the growth of dense fibrous or 
connective tissue around the tumor (Figure 4.2a and b).  Several of these tumors show 
increased tumor infiltrating lymphocytes (Figure 4.2b and c).  These tumors were not 
reported to be inflammatory breast cancer (IBC).  IBC is caused by blockage of the dermal 
lymphatics by infiltration of tumor cells, rather than an infiltration of inflammatory cells. In 
addition, unlike Claudin-low tumors, IBC tumors have not been shown to produce high 
levels of inflammatory cytokines and inflammatory cells are only rarely detected around 
tumor stroma.  These Claudin-low tumors are not invasive lobular carcinomas (ILC), which 
are also breast tumors that show low levels of E-cadherin.  In ILC, E-cadherin is typically 
low due to the result of an E-cadherin mutation.  ILC also have a distinct morphology and are 
usually ER-positive, whereas Claudin-low tumors are predominantly clinically ER and HER2 
negative (Table 4.1) and therefore would be defined as triple negative. 
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Figure 4.2. Morpological features of Claudin-low tumors.  Claudin-low tumors  
are mostly high grade ductal carcinomas associated with marked stromal  
desmoplasia (a,b).  Several of these tumors show increased tumor infiltrating lymphocytes 
(b,c). 
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Gene expression signature associated with Claudin-low breast carcinomas 
To determine the gene expression signature associated with the Claudin-low subtype, 
a 2-class Significance Analysis of Microarrays (SAM) was performed[5].  In total there were 
1704 genes identified with a false discovery rate of 1%.  1107 genes were significantly 
highly expressed regulated in Claudin-low tumors.  An analysis of Gene Ontology showed 
that categories of immune and inflammatory response were the top biological processes with 
Bonferroni-corrected significant enrichment scores in this gene list (Table 4.2).  These 
tumors show a marked increased expression of B cell markers (CD19) and T cell markers 
(CD3z and CD3g).  One of the top genes in the SAM list was the general lymphocyte 
marker, CD45, which again suggests the presence of immune cell infiltrates in Claudin-low 
tumors. 
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Claudin-low tumors also express Snail, Slug, and Twist 2; transcription factors (or 
family members thereof in the case of Twist 2) that have been shown to repress the 
transcription of E-cadherin and that are involved in the process of epithelial-to-mesenchymal 
transition (EMT)[6-8].  Reduced E-cadherin expression can also be associated with abnormal 
expression of P-cadherin, N-cadherin, or Cadherin-11.  This has been coined the “cadherin 
switch”.  Neither N-cadherin nor P-cadherin, which is high in basal-like tumors, were highly 
expressed in the Claudin-low subtype.  Interestingly, Cadherin-11 was expressed at higher 
levels in Claudin-low tumors. 
 
597 genes were significantly negatively regulated in Claudin-low tumors including 
tight junction associated genes (Claudin 3, E-cadherin, Occludin, and tight junction protein 
2). Significant ontology categories enriched in this list included genes involved in chromatin 
and nucleosome assembly (Table 4.2).  As we noticed from the intrinsic cluster, Claudin-low 
tumors also showed low expression of luminal epithelial signature genes (Keratin 8, ER, 
XBP1, FOXA1, and GATA3). 
 
Claudin-low tumors express low levels of tight junction associated proteins by IHC 
In order to validate these gene expression results, we performed IHC for Claudin 3 
and E-cadherin on 15 basal-like, 32 luminal A, 14 luminal B, 13 HER2+/ER- and 19 claudin-
low tumors.  Over half of the Claudin-low tumors either showed no staining (3/19) or weak 
positive (1+) staining for Claudin 3 (8/19) (Figure 4.3, Table 4.3a).  No tumors from any of 
the other subtypes showed a complete lack of Claudin 3 staining.  The majority of tumors 
from each non-Claudin-low subtype, Basal-like (13/15), Luminal A (21/32), Luminal B 
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(13/14), Normal-like (7/8), and HER2+, ER- (8/13) scored either moderate or strong positive 
(2 or 3+) staining results.  The results were similar for E-cadherin staining (Figure 4.3, Table 
4.3b) where more than half of the Claudin-low tumors (10/19) were scored 0 or 1+.  By 
comparison, Basal-like (13/15), Luminal A (24/32), Luminal B (12/14), Normal-like (8/8), 
and HER2+, ER- (12/13) were scored either moderate or strong positive (2 or 3+).  These 
results were consistent, however, but not as dramatic as the gene expression data.  A possible 
explanation is that tumors show heterogeneity for loss of expression of these proteins and 
detection depends on the section that is taken for staining.  It also should be noted that while 
the low expression of Claudin 3 and E-cadherin are distinct, intrinsic, features of the Claudin-
low subtype, these characteristics are not unique to Claudin-low tumors and appear to be 
characteristic of subsets of tumors in other subtypes as well (Figure 4.1). 
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Figure 4.3. Immunophenotype of Claudin-low tumors.  Claudin-low tumors (a,b,e,f)  
often show lower expression of Claudin 3 and E-cadherin than basal-like (d,h) and luminal 
tumors(c,g). 
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DISCUSSION 
In this report, we present the identification and characterization of a new molecular 
subtype of breast cancer identified by intrinsic clustering.  This subtype shows a low 
expression of tight junction associated genes.  These tumors show high expression of 
immune genes and lymphocyte markers, which are features that were confirmed by the 
histology that shows the presence of many lymphocytic infiltrates.  Loss of E-cadherin, 
usually by mutation and accompanying loss of heterozygosity, is a very common feature of 
invasive lobular carcinomas (ILC)[9].  Histology and estrogen receptor status rule out the 
Claudin-low tumors in this study as being ILC.  Complete loss of E-cadherin has been 
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reported in IDC[9].  Mutations are not seen in IDC, however, E-cadherin LOH is a relatively 
common event.   
 
E-cadherin expression can be regulated at the transcriptional level by repressors 
including Snail, Slug (Snail2), and Twist[6-8].  Snail, Slug, and Twist 2 are all highly 
expressed in Claudin-low tumors.  Snail expression has been shown to correlate with 
histological grade and lymph node status in breast carcinomas[6].  It was also noted in this 
study that some dedifferentiated tumors also expressed Snail and were node negative.  Snail 
has also been shown to promote tumor recurrence in a mouse mammary tumor model[10].  
Concurrent with losing E-cadherin, Claudin-low tumors appear to gain expression of 
Cadherin-11.  Normally, Cadherin-11 is found preferentially in mesenchymal tissues, but it 
has been detected in invasive breast carcinoma cell lines[11].  Cadherin-11 has also been 
shown to promote tumor cell motility and invasiveness and there has been a reported 
correlation between expression of Cadherin-11 and enhanced metastastic potential[12].  The 
presence of a Cadherin-11 splice variant has been suggested to promote invasion[13].  The 
expression of this gene thus needs to be validated by IHC to determine if in fact high protein 
expression is a feature of the tumor cells or limited to the tumor associated stroma. 
 
The Claudin-low subtype makes up only about 3-5% of breast cancers, however, if 
almost 200,000 new cases arise each year in the United States, then that equals 6-12,000, 
which is a significant number of patients. In this study we determined and validated using 
IHC some of the genes/proteins that showed low expression in these tumors.  Due to the high 
expression of genes presumably coming from infiltrative lymphocytes in these tumors, it is a 
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challenge to find positive IHC markers to identify this tumor class.  These finding when and 
if they occur, should assist in the prospective and retrospective identification of Claudin-low 
breast tumor clinical specimens, which will facilitate further molecular, epidemiologic, and 
treatment studies of this rare and unique tumor subtype. 
 
 
MATERIALS AND METHODS 
Significance analysis of microarrays (SAM) and gene ontology analysis   
SAM analysis was performed to identify genes that were significantly different between 
Claudin-low tumors compared with the remaining samples[5].  Expression analysis systemic 
explorer (EASE) was used to identify gene ontology categories overrepresented in the 
Claudin-low gene list compared to the genes present on the array. 
 
Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue sections (~5um) were processed using standard 
immunostaining methods. Following deparaffinization in xylenes, slides were rehydrated 
through a graded series of alcohol and rinsed in phosphate buffered saline. Endogenous 
peroxidase activity was blocked with 3% hydrogen peroxidase. Samples were steamed for 
antigen retrieval with 10 mM citrate buffer (pH 6.0) for 30 min.  Slides were then incubated 
for 20 minutes with diluted normal blocking serum.  The sections were incubated for 60 
minutes at room temperature with primary antibody to claudin 3 (Zymed 18-7340 1:100) or 
e-cadherin (Cell Marque ECH-6 pre-diluted) .  The slides were incubated for 45 minutes with 
diluted biotinylated secondary antibody (1:250 dilution) and 30 minutes with Vectastain Elite 
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ABC reagent (Vector Laboratories). Sections were incubated in peroxidase substrate solution 
for visualization.. Slides were counterstained with hematoxylin and examined by light 
microscopy.  Tumor immunoreactivity was scored 0=negative, 1=weak positive,  2=moderate 
positive, and 3=strong positive.   
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CHAPTER V 
LOSS OF THE RETINOBLASTOMA TUMOR SUPPRESSOR IS A COMMON EVENT 
IN BASAL-LIKE AND LUMINAL B BREAST CARCINOMAS 
 
PREFACE 
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performed data analysis, scoring of IHC staining, development of the figures, and the writing 
of the manuscript.   Xiaping He prepared DNA from tumors and normal patient lymphocytes, 
and IHC staining and scoring.  Cheng Fan assisted with the data analysis.  Charles Perou was 
the Principal Investigator, conceived and designed the study, and helped draft the paper. 
 
Jason I Herschkowitz, Xiaping He, Cheng Fan, and Charles M. Perou. (2007) Loss of the 
retinoblastoma tumor suppressor is a common event in Basal-like and Luminal B breast 
carcinomas. [in preparation]
SUMMARY 
 
Breast cancers can be classified using whole genome expression into distinct subtypes 
that show differences in patient prognosis.  One of these groups, the basal-like carcinomas, 
are poorly differentiated, highly metastatic, and genomically unstable.  These tumors also 
contain specific genetic alterations with one example being frequent p53 mutations.  The loss 
of the tumor suppressor gene encoded by the retinoblastoma (RB1) locus is a well-
characterized occurrence in many tumor types. However, its role in breast cancer is less clear 
with many reports demonstrating a Loss of Heterozygosity (LOH), but which does not 
correlate with loss of RB1 protein expression.  Here we report that LOH of the RB1 locus 
was observed at a high frequency in basal-like and luminal B tumors.  These tumors also 
concurrently have low expression of RB1 mRNA as assessed by DNA microarray.  As in 
previous reports, we did not see a significant correlation between RB1 LOH and protein 
expression as measured by immunohistochemistry (IHC).  p16INK4a, however, was highly 
expressed both by microarray and IHC, in basal-like tumors presumably due to a previously 
reported feedback loop caused by RB1 loss.  These results suggest that the functional loss of 
RB1 is a common event in the progression of basal-like and luminal B breast tumors, which 
may play a key role in dictating therapeutic responses.     
 
SIGNIFICANCE 
Gene expression profiling has separated breast tumors into clinically prognostic 
subtypes, however, many of the underlying causative mutations are still not known.  Here we 
report that LOH at the RB1 locus was observed at a high frequency in two subtypes (basal-
like and luminal B tumors), both of which are highly proliferative. In addition, in basal-like 
 111
tumors, the RB1 LOH is also accompanied by the high expression of p16. The loss of RB1 is 
likely to play a key role in the distinct poor prognosis and response to treatment that is 
characteristic these subtypes. 
 
 
INTRODUCTION 
The retinoblastoma tumor suppressor gene (RB1) encodes a nuclear phosphoprotein 
that plays a central role in the regulation of the cell cycle.  Inactivation of both alleles of this 
gene is involved in the development of retinoblastoma, which is a rare childhood 
malignancy.  The loss of RB1 is also a well-characterized occurrence in many other human 
tumor types and it is likely that the p16-RB pathway is disrupted in most human tumors[1].  
RB1 regulates progression through the G1 to S-phase transition of the cell cycle.  In cells 
entering the cell cycle, extracellular signals induce the expression of D-type cyclins, which 
bind to and activate cyclin-dependent kinases (CDK4 and CDK6); these complexes in turn 
lead to the phosphorylation of RB, its dissociation from E2F family members that then 
transcriptionally activate many genes required for S phase.  The INK4 family of cyclin-
dependent kinase inhibitors (p16INK4a, p15INK4b, p18INK4c, and p19INK4d) inhibit CDK4 and 
CDK6 retaining RB in its hypo-phosphorylated E2F associated state, therefore preventing G1 
to S-phase progression.  It has recently been shown that CDK4 and CDK6 (and CDK2) are 
dispensable for driving the essential cell cycle, however they are required in specialized 
tissues and possibly to achieve higher levels of proliferation[2]. 
 
 112
Inactivation of the RB1 gene in breast cancer was originally shown using a series of 
cell lines[3].  Subsequently, loss of heterozygosity (LOH) has been observed in primary 
tumors, but does not necessarily correlate with loss of RB1 protein expression by IHC[4, 5].  
LOH has, however, been shown to correlate with RB1 mRNA low expression [4].  There are 
also events upstream of RB1 that may be present in breast tumors, which can negatively 
impact RB function by promoting its phosphorylation that include p16INK4a loss[6] and 
cyclin D1 amplification/overexpression[7] 
 
Breast cancer is a heterogeneous disease, which is separable into clinically significant 
subtypes as defined by molecular profiling[8, 9].  In addition to reproducible gene expression 
differences between these subtypes, specific molecular alterations continue to be identified 
that correlate with each subtype.  Tumors of the basal-like subtype generally have a high 
mitotic index, tend to be p53 mutated [10] and highly express the proliferation signature, 
which is a gene cluster shown to contain many E2F target genes[11, 12].  Here we report that 
LOH at the RB1 locus occurs at a high frequency in basal-like and Luminal B tumors, while 
occurring infrequently in Luminal A and HER2+/ER- tumors.  Many of these tumors also 
concurrently have low expression of RB1 mRNA as assessed by DNA microarray.  
p16INK4A is also highly expressed both by microarray and by IHC in most of these RB1 
LOH basal-like tumors presumably due to a feedback caused by RB1 loss.  These results 
further illustrate the unique biology of the basal-like subtype.    
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RESULTS 
Basal-like tumors show low expression of the RB1 transcript 
Tumors of the basal-like subtype have been shown in several studies to have a high 
mitotic rate and to highly express a proliferation gene signature[10, 11].  For this reason, we 
postulated that there might be a defect in the RB pathway in these tumors.  We first examined 
the expression levels of the core components and regulators of the RB pathway in a 
previously published microarray data set[8, 13] that contains 232 microarrays consisting of 
184 primary breast tumor samples and 9 normal breast samples (Figure 5.1).  On average, 
RB1 was expressed at the lowest levels in basal-like tumors and at the highest levels in 
luminal A tumors (Figure 5.1 and 5.2A).  Tumors of the basal-like subtype also frequently 
showed high levels of p16 INK4A (Figure 5.1 and 5.2B) and E2F1 (Figure 5.1 and not 
shown).  Cyclin D1 levels, on the other hand, were elevated in mainly luminal tumors 
including noticeably higher expression in many Luminal B tumors (Figure 5.1 and 5.2C); in 
addition, it was recently reported that there are often high level gains of the 11q13 locus that 
includes Cyclin D1 in luminal tumors (A and B)[14], thus suggesting that Cyclin D1 high 
expression can be considered a “luminal event”.   
 
 
LOH at the RB1 locus is a common event in breast cancer associated with high 
proliferation 
Due to the low expression of RB1 message in basal-like tumors we decided to 
examine these breast carcinomas for LOH at the RB1 locus. We investigated 88 paired 
primary human breast carcinomas and normal tissue genomic DNA samples to assess the 
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frequency of LOH in RB1.  We used two polymorphic markers located at the RB1 locus 
(13q14); a variable number tandem repeat (VNTR) in intron 20 and D13S153, a 
microsatellite marker located within intron 2.  There were 67 cases that were informative for 
at least one of these two markers.  In total, 26 tumors showed RB1 LOH for at least one 
marker (26/67 38.8%).  This is consistent with the frequency of RB1 LOH seen in previous 
studies of breast cancer (26-47%)[4, 5, 15].   
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Figure 5.1 The expression of retinoblastoma pathway members varies across breast 
cancer intrinsic subtypes.  232 human samples are ordered by subtype according to the 5-
class single sample predictor from Hu et al. 2006[8]. Samples are colored according to their 
subtype: red=Basal-like, dark blue=Luminal A, light blue=Luminal B, pink= HER2+/ER-, 
and green=Normal breast-like.  a) proliferation gene cluster  b) Rb pathway genes which are 
present on array and pass filtering criteria. 
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Figure 5.2 The expression of RB1, p16INK4a, and Cyclin D1 varies across the breast 
cancer intrinsic subtypes.  Box plot comparisons of a) RB1, b) p16INK4a, and c) Cyclin D1 
mRNA expression to five intrinsic subtypes as defined by 5-class SSP. 
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Next, using a previously defined proliferation gene signature [8], we clustered the 
gene expression data for this signature using just the 67 LOH informative patients (Figure 
5.3A).  This analysis was able to sort the samples into two groups with the right most group 
containing most of the RB1 LOH+ tumors (21/27 77.7%).  The left most group contained 
29/40 (72.5%) of the RB1 LOH-normal tumors. It is important to note, however, that many 
of the LOH+ tumors that did cluster in the left group, were located on the outer nodes and 
still showed high expression of the proliferation markers than the tumors in the center.  
Overall, ANOVA analysis showed that RB1 LOH is highly correlated with high expression 
of the proliferation gene cluster (p=0.0001) (Figure 5.3B). 
 
LOH at the RB1 locus is associated with tumor subtype 
We classified the tumors according to intrinsic subtype using the 5-class single 
sample predictor (SSP) from Hu et al[8].  The frequency of RB1 LOH varied by molecular 
subtype (p=0.0002) (Table 5.1).  The lowest LOH frequencies were observed in the Luminal 
A (3/20 15%) and Normal-like (0/7 0%) subtypes, while the HER2+/ER- subtype had a 
frequency near the breast cancer average (3/9 33.3%).  The highest frequency of RB1 LOH 
was observed in tumors of the basal-like subtype (13/18 72.2%) and the Luminal B subtype 
(8/13 61.5%), both of which are known to be highly proliferative tumor subtypes[8-10]. 
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Figure 5.3 RB1 LOH is associated with high proliferation. a) two-way unsupervised 
hierchical clustering of breast tumor samples with informative RB1 LOH status (LOH + = 
blue, LOH - = yellow) using the proliferation gene cluster.  b) Box plot comparison of the 
average proliferation cluster expression to RB1 LOH status (p<0.0001). 
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RB1 and P16INK4A immunostaining in breast carcinomas 
RB1 is expressed ubiquitously in mammary epithelial cells and typically shows a 
nuclear staining pattern in normal human breast tissue (Figure 5.4a).  RB1 immunostaining 
was statistically correlated with RB1 message levels (p=0.0081), however as has been 
described before, RB1 protein expression did not correlate with RB1 LOH (p=0.5) [5]; 
however, a trend for low expression of RB1 message to occur with RB1 LOH was observed 
(p=0.11). RB1 protein expression trended to be low in basal-like tumors (Figure 5.4b and 
Table 5.1), however, this relationship was also not statistically significant (p=0.064). 
 
High p16INK4a staining (3+), which is likely a hallmark of lost RB1 function [16, 
17], was seen in 32/119 tumors assayed and often included both nuclear and cytoplasmic 
staining.  p16INK4a immunostaining was statistically correlated with p16INK4a message 
levels (p=0.013), especially when there was high staining observed (Appendix VA).  
p16INK4a immunostaining was also associated with molecular subtype (p=1.41E-05) with 
22/33 (66.7%) of basal-like tumors showing 3+ staining (Figure 5.3c, Table 5.1).  The 
correlation between RB1 LOH status and p16INK4a gene expression levels was also 
statistically significant (p=0.01) (Figure 5.3f).  In addition, p16INK4a is similarly highly 
expressed in transgenic murine mammary tumors with loss of Rb function driven by SV40 
large T-antigen or T121 (Appendix VB)[13]. 
 
 
 
 
 123
  
 
 
 
 
 
 124
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4 High p16INK4a mRNA and protein levels are associated with RB1 LOH. a) 
RB1 staining of normal breast tissue b) RB1 LOH + basal-like tumor lacking RB1 staining 
and c) showing heavy staining for p16INK4a both nuclear and cytoplasmic.  d) comparison 
of p16INK4a IHC and RB1 LOH status. (p16 0=negative, 1=weak positive, 2=moderate 
positive, 3=strong positive) e) Box plot comparison showing high p16INK4a mRNA 
expression in RB1 LOH + breast tumors (p=0.01). 
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RB1 LOH gene expression signature 
To determine if there was a gene expression signature related to RB1 LOH, a 2-class 
Significance Analysis of Microarrays (SAM) was performed[18].  In total there were 452 
genes that varied with RB1 LOH status with a false discovery rate of 0.94%, as compared to 
11 genes identified at a FDR of 16.7% when a similar analysis was performed using RB 
immunostaining data (0 vs 1,2,and 3).  423 of these genes were highly expressed in tumors 
with RB1 LOH and an analysis of the Gene Ontologies associated with this gene set showed 
that cell cycle, cell division, DNA metabolism, spindle organization and biogenesis, and 
response to DNA damage were the top biological processes when using Bonferroni-corrected 
scores. Interestingly, E2F1, E2F3, and E2F5 are highly expressed in tumors with RB1 LOH.  
Also present in this list is RB1CC1, a regulator of RB1 expression that has been shown to 
contain truncating mutations in breast cancers[19].  We used whole genome RVista to 
calculate which transcription factor binding sites might be present within the 1000bp 
upstream regions of these genes [20] and determined that the top three transcription factor 
binding sites with p<0.005 were E2F4DP1, E2F1DP1RB, and E2F4DP2, showing that a 
majority of these genes are likely E2F-regulated; other statistically significant transcription 
factor binding sites were HIF1/ARHN-HIF1. Only 29 genes were significantly 
negatively/down regulated from the RB1 LOH SAM analysis, and there were no significant 
Gene Ontology categories enriched in this list.   
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RB1 LOH gene expression signature correlates with signatures of proliferation and RB-
loss 
Recently, an RB-loss gene expression signature was derived using mouse fibroblasts 
with either acute or chronic knockout of RB using RNAi[21].  As might be expected, this 
RB-loss signature was highly expressed in basal-like tumors (Appendix VD).  This RB-loss 
signature showed overall in gene identify with the proliferation signature (29/139 genes of 
the RB-loss signature are contained in the 140 gene human proliferation signature used here), 
thus serving as further evidence that the proliferation signature contains many RB-E2F 
regulated genes.  There was statistically significant overlap among all three RB-pathway 
signatures (RB-LOH, RB-loss, and proliferation) as determined by hypergeometric mean 
analysis p<0.001 (Figure 5.5, Appendix VC), thus all three signatures are likely tracking a 
common biology that is RB-E2F dependent.  There were 20 genes which overlapped between 
all three gene lists, which included many cell cycle related genes including the spindle 
assembly checkpoint proteins BUB1 and MAD2 and many commonly used 
chemotherapeutic drug targets including TOP2A (doxorubicin, etoposide), thymidylate 
synthetase (5-FU),  ribonucleotide reductase M2 (hydroxyurea), and CDC2 (flavopiridol, 
staurosporine).   
 
 
 
 
 
 
 128
     
Figure 5.5 Venn diagram showing the significant overlap between the Rb LOH, 
proliferation, and Rb-regulated gene lists. 
 
All four of these RB-pathway associated lists (RB-LOH, RB-loss, proliferation 
signature and 20 common genes) were highly predictive of breast cancer patient outcomes 
when using a 2-class, or 3-class, average value rank order expression cutoff and tested on the 
NKI295 patient data set (Figure 5.6 using RB-LOH list, all 4 lists give very similar 
results)[22], and on the Miller et al. 251 patient data set (data not shown)[23]. It should be 
noted, however, that multiple different investigators have independently identified different 
gene lists that contain a large number of so called proliferation/RB-pathway genes [12, 24-
27], thus it is not unexpected that the RB-LOH signature is a strong prognostic profile. 
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Figure 5.6 RB-LOH gene list is highly predictive of breast cancer patient outcome.  
Kaplan Meier survival curves looking at overall survival (OS) or relapse free survival (RFS) 
by dividing the patients in thirds (A,C) or in half (B,D) using the RB-LOH expression 
signature on the NKI295 breast cancer dataset 
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 DISCUSSION 
 
Our understanding of breast cancer biology has been improved by the identification 
of genomically defined tumor subtypes. These subtypes are defined by distinct gene 
expression patterns, molecular changes, and potential distinct developmental cell types of 
origin adding up to observed differences in outcome and responses to therapy.  In this report, 
we show that the frequency of RB1 LOH observed varied significantly according to 
“intrinsic” subtype.  RB1 LOH occurs at a frequency of 72.2% in basal-like breast tumors 
and 61.5% in Luminal B tumors, both of which are in the range of the 60-75% frequency 
observed in retinoblastomas[28-31]. RB1 protein staining as assessed by IHC, however, did 
not correlate with RB1 LOH in our study (as has been reported before); however, a SAM 
analysis supervised by RB1 LOH robustly identified many E2F genes, and E2F target genes, 
while the RB protein SAM analysis did not (data not shown), which suggests that RB1 LOH 
is a better biomarker of RB-pathway function than IHC staining for total RB protein. 
 
Additional support for the functional loss of RB function in basal-like tumors comes 
from the correlation with high p16INK4a message and protein. The inverse relationship 
between p16INK4a and RB1 expression in breast cancers has been reported before[32, 33], 
however, this relationship and it association with basal-like tumors is new. Another 
intriguing link between p16INK4a and basal-like cells comes from studies on HMECs 
(human mammary epithelial cells), which have been shown to resemble the basal-like 
subtype by gene expression [34, 35]. It has been shown that in order for HMECs to 
proliferate in culture for an extended period in vitro they must overcome an RB-mediated 
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stress associated senescence barrier (stasis), which usually involves spontaneously losing p16 
expression by promoter methylation [36]; the gene expression changes associated with this in 
vitro transition are similar to those we have reported occurring with RB1 LOH[37]. In vivo in 
basal-like tumors, however, the exact opposite appears to occur in that the RB-pathway 
barrier appears to be RB functional loss with a concomitant feedback loop that induces p16 
gene and protein expression. The link between high p16 expression being caused by RB1 
loss is known it has been shown that RB1 recruits Polycomb repression complexes to the p16 
locus, which silence p16/INK4a transcription[38].  It is also well-known that cell cycle 
inhibition by p16INK4a is RB-dependent[39], and therefore, these RB1 deficient breast 
tumors would be expected to be refractory to the high amounts of p16INK4a present, which 
explains their high proliferation rates in the presence of the highest levels of p16.  High 
p16INK4a expression has reproducibly been shown to be associated with poor prognosis [32, 
40-42] and in a recent study by Grupka et al., p16INK4a staining of sentinel lymph nodes 
was predictive in determining the presence of non-sentinel node metastases[43].  In total, 
these data strongly argue that the RB-pathway lesion that occurs in most basal-like tumors is 
RB loss, with a compensatory activation of p16. Lastly, basal-like tumors also highly express 
a recently published RB-loss gene expression signature [21, 24], which we have shown to 
have significant similarity to the previously defined proliferation signature and our newly 
described list of genes that correlate with RB1 LOH.  The elevated Ki-67 index seen in basal-
like ductal carcinoma in situ lesions also suggests that RB1 loss may be an early event for 
this tumor type[44].   
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Similar to basal-like tumors, Luminal B tumors also showed a high frequency 
(61.5%) of RB1 LOH in our study, but did not show an association with high p16 expression.  
In the recent study by Bosco et al., luminal tumor derived cell lines were shown to be more 
proliferative and resistant to hormone therapy following knockdown of RB1[24], both of 
which are signatures of Luminal B tumors [8-10].  The RB-loss signature was shown to be 
predictive of outcome in a dataset containing only ER+ breast tumors treated with tamoxifen 
monotherapy.  Therefore, the loss of RB1 function may also play a substantial role in the 
increased proliferation, possible resistance to hormonal therapies, and poor prognosis that is 
seen in Luminal B tumors. In addition, the knockdown of RB1 in established breast cancer 
cell lines has recently been shown to increase sensitivity to a variety of DNA-damaging 
therapeutic agents[24].  While these experiments were performed with ER+ tumor cell lines, 
it does open the possibility that the RB1 defect in basal-like tumors plays a role in their 
increased chemosensitivity compared to luminal tumors [45, 46].   
 
The presence of LOH is typically thought to indicate that a mutated allele is present 
on the other chromosome and that the LOH unmasks the mutated allele. However, there is 
little evidence to suggest that dramatic structural changes aside from LOH are occurring at 
the RB1 locus in breast tumors. There are a few reports of alterations in RB1 in breast cancer 
with two reports showing structural changes as assessed by southern blotting in 7% and 19% 
of primary tumors[47, 48], and no published reports to our knowledge of point mutations. 
Interestingly, a study by Kallionemi et al. looking at RB1 loss in clinical breast cancer 
samples by fluorescent in situ hybridization showed that most of the cells within these tumors 
contained two copies of the RB1 gene even when they showed LOH by restriction fragment 
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length polymorphism at the RB1 locus[49].  When these studies are considered with the data 
presented here, they suggest a complex scenario where one allele is lost or altered in function 
by LOH, and the remaining allele/residual protein is compromised by yet to be identified 
mechanism(s) that potentially varies between tumor subtype, and potentially varies even 
within basal-like tumors; for example, some basal tumors with LOH show complete loss of 
RB protein, while others show high expression and both types show high proliferation. Thus 
additional studies will be needed to define these unconventional methods of RB1 
inactivation. 
 
In summary, here we show that RB1 LOH is a frequent occurrence in basal-like and 
luminal B breast tumors and is associated with deregulation of E2F-regulated genes and 
increased proliferation.  Deregulation of the Rb pathway in cell lines has shown that it may 
be an important determinant of response to therapy[24].  Therefore, RB function would 
appear to be an important biomarker for informing treatment decisions.  Future studies 
involving clinical trials are warranted to evaluate the impact RB1 loss has on therapeutic 
response in breast cancer overall and within molecular subtypes.  
 
EXPERIMENTAL PROCEDURES 
 
Patient samples and breast cancer microarray data sets  
All human tumor samples were collected from fresh frozen primary breast tumors 
using IRB-approved protocols and were profiled as described previously[8, 13, 50, 51]. The 
clinical and pathological information for these samples can be obtained online shortly. 
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The primary microarray data for the 232 dataset is available at genome.unc.edu and in GEO 
under the accession number GSE3165.  The data set containing only tumors with informative 
LOH status will be found in GEO shortly. 
 
DNA isolation and detection of RB1 loss of heterozygosity 
Patient DNA from lymphocytes and breast tumors was isolated using the DNeasy kit 
(Qiagen).  We used two polymorphic markers, a variable number tandem repeat (VNTR) in 
intron 20 and D13S153; a microsatellite marker.  The primers were previously published for 
intron 20 [52].  The primers for D13S153 (AFM058xd6a, AFM058xd6m) were obtained 
from the Genome Data Bank (http://www.gdb.org/) (Johns Hopkins University).  The PCR 
products were run on the Agilent Bioanalyzer using DNA 1000 kit (Agilent).  The patient 
was called informative when there were two alleles present in their normal DNA.  LOH was 
called when there was a loss of an allele in the tumor for at least one of the two polymorphic 
sites. 
 
Statistical Analysis 
The Chi-Square test and Fisher-Freeman-Halton Exact test were used to examine 
correlations between RB1 LOH status, immunostaining, and tumor subtype using SAS 9.1 
(Cary, NC).  ANOVA analysis, unpaired Student's t-test and box plot were performed to 
compare RB1 LOH status or immunostaining, with gene expression using web based 
"Statistists to Use" at http://www.physics.csbsju.edu/stats/  
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SAM analysis was performed to identify genes that were significantly different 
between tumors with RB1 LOH + compared to LOH - tumors[18].  Expression analysis 
systemic explorer (EASE) was used to identify gene ontology categories overrepresented in 
the RB LOH gene list compared to the genes present on the array. 
 
Whole genome RVista ( http://genome.lbl.gov/vista/index.shtml ) was used to 
determine the known transcription factor binding sites overrepresented in the 1kb upstream 
region in the lists of genes examined compared to the rest of the RefSeq genes in the whole 
human genome[20] 
 
Hypergeometric mean analysis was performed as in Chung et al[53]. Briefly, the 
simulation was performed by randomly selecting a set of genes from the entire overlapping 
population of genes from which each pair of test gene sets were derived. The number 
randomly selected was set to the number of genes in our subset being tested. This randomly 
selected set was then compared for overlap, with the corresponding gene sets that were 
mentioned from published studies. The number of genes found in the overlap was recorded 
and the process was repeated 10,000 times. In the final step, the actual amount of overlap 
was compared between our gene set and the published gene sets, and this was compared to 
the simulated distribution. This comparison gives the likelihood of finding co-occurrences 
between these gene sets by chance. The simulation was performed independently for each 
pair of gene sets. 
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Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue sections (~5um) were processed using 
standard immunostaining methods. Following deparaffinization in xylenes, slides were 
rehydrated through a graded series of alcohol and rinsed in phosphate buffered saline. 
Endogenous peroxidase activity was blocked with 3% hydrogen peroxidase. Samples were 
steamed for antigen retrieval with 10 mM citrate buffer (pH 6.0) for 30 min.  Slides were 
then incubated for 20 minutes with diluted normal blocking serum.  The sections were 
incubated for 60 minutes at room temperature with primary antibody pRb (Visionbiosystems 
Novocastra, NCL-L-RB-358 clone 13A10, 1:50 dilution) or p16 (Santa Cruz, H-156, 1:50 
dilution).  The slides were incubated for 45 minutes with diluted biotinylated secondary 
antibody (1:250 dilution) and 30 minutes with Vectastain Elite ABC reagent (Vector 
Laboratories). Sections were incubated in peroxidase substrate solution for visualization.. 
Slides were counterstained with hematoxylin and examined by light microscopy.  Tumor 
immunoreactivity was scored 0=negative, 1=weak positive,  2=moderate positive, and 
3=strong positive.  The evaluation of p16 and Rb staining was performed by two independent 
researchers.   
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CHAPTER VI 
CONCLUSIONS 
 
There are many model systems in which to study breast cancer, each with their 
inherent advantages and disadvantages[1].  We turned to the mouse because we desired a 
model that will give us the ability to study spontaneous tumor development and therapy 
response in vivo.  Furthermore, the mouse is amenable to genetic manipulation.  Due to the 
heterogeneity of breast cancer, one model is not adequate.  Luckily, there are many mouse 
mammary tumor models that have been generated over the past twenty years.  In order to use 
these models in the most relevant way, the question we first had to answer was how do these 
mouse models relate to the human subtypes of breast cancer?  Which models mimic aspects 
of human breast cancer and therefore may be useful to further study in a relevant way?  It is 
not always clear which features of a human cancer are most relevant for disease comparisons 
(e.g. genetic aberrations, histological features, tumor biology). Genomic profiling provided 
us with a tool for comparative cancer analysis and offered a powerful means of cross-species 
comparison.  We used gene expression analysis to classify a large set of mouse mammary 
tumor models and human breast tumors. The results provided us with biological insights 
among and across the mouse models, and comparisons with human data have identified 
biologically and clinically significant shared features. 
 
These studies have highlighted what we feel are the two major applications for 
genomic comparisons between human tumors and their potential murine counterparts. First, 
these studies have identified those models that contain individual and/or global 
characteristics of particular classes of human tumors.  Examples of important across-species 
biological characteristics identified in our studies included the classification of murine 
tumors, like human tumors, into basal and luminal groups. In our original study, four murine 
models developed potential luminal-like tumors (TgMMTV-Neu, TgMMTV-PyMT, 
TgWAP-Myc, and TgWAP-Int3), which is not surprising since both MMTV and WAP are 
thought to direct expression in differentiated alveolar/luminal cells [2, 3].  The luminal 
profile in the mouse models, however, lacked the expression of ER and ER-regulated genes 
and thus, there appears to be no murine counterpart of human Luminal A tumors. 
 
Several murine models did show expression features consistent with human basal-like 
tumors including the TgC3(1)-Tag, TgWAP-Tag and Brca1-deficient models. The SV40 T-
antigen used in the TgC3(1)-Tag and TgWAP-Tag models inactivates p53 and RB, which 
also appear to be two likely events that occur in human basal-like tumors because these 
tumors are known to harbor p53 mutations[4], have high mitotic grade and the highest 
expression of proliferation genes [4, 5], which are known E2F targets[6]. The proliferation 
signature in human breast cancers is itself prognostic[7], and is also predictive of benefit to 
chemotherapy in ER+ patients [8]. 
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We found that Brca1 loss (coincident with p53 mutation), in mice gives rise to tumors 
with features of basal-like human tumors.  This finding was notable because human BRCA1 
germline mutation carriers almost exclusively develop basal-like tumors[5, 9].  In addition, 
most human BRCA1 mutant tumors are p53-deficient[10, 11], which is required in these 
models to generate tumors with a reasonable latency and penetrance.  Interestingly, a recent 
report also shows that conditional loss of BRCA1 and p53 using K14-Cre in mice induces 
mammary tumors also with a human basal-like breast cancer phenotype[12].  This looks to 
be a more consistent phenotype than the MMTV-Cre model showing the importance of the 
choice of promoter. 
 
These data suggest a conserved predisposition of the basal-like cell type, or its 
antecedent cell, to transform as a result of BRCA1, TP53, and RB-pathway loss. Most 
DMBA-induced carcinomas also showed basal-like cell lineage features, suggesting that this 
cell type is also susceptible to DMBA-mediated tumorigenesis. Finally, some TgMMTV-
Wnt1 tumors showed a combination of basal-like and luminal characteristics by gene 
expression, which is consistent with the observation that tumors of this model generally 
contain cells from both mammary epithelial lineages[13].   
 
With these luminal and basal distinctions, our comparison of mouse models has 
begun to hint at the cell types of origin of these tumors and the human tumors they mimic.  
Studying the cellular origins of cancers, whether the result of transformation of a stem cell, 
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progenitor cell, or de-differentiation of a mature cell, is a challenging task in human model 
systems and mouse models should be more amenable to this task. 
 
The second major result of this comparative study was showing that analyses of 
murine models can inform the human disease and guide further discovery. An example of 
murine models informing the human disease is encompassed by the analysis of the new 
potential human subtype discovered here which we refer to as claudin-low.  We have begun 
to further analyze these tumors to confirm that this is a bona fide subtype. The statistically 
significant gene overlap with a histologically distinct subset of murine tumors suggests that it 
is a distinct biological entity.   This human subtype is defined by the low expression of genes 
involved in tight junctions and cell-cell adhesion including Claudins 3 and 12, Occludin, and 
E-cadherin. These tumors also show a marked increased expression of lymphocyte markers 
validated by the increased tumor infiltrating lymphocytes seen on examination.  Consistent 
with their transcriptional profiles, immunohistochemical analysis showed that most claudin-
low tumors expressed Claudin 3 and E-cadherin at low levels. 
 
A second example of the murine tumors guiding discovery in humans was the 
common association of a K-Ras containing amplicon in a subset of human basal-like tumors 
and in the murine basal-like TgC3(1)-Tag strain tumors.  Previous reports have shown that 
K-Ras is important for tumor progression in the TgC3(1)-Tag model.  We have now begun to 
look further for copy number gains and losses in regions of conserved synteny that are in 
common between tumors arising in mouse models and human breast tumor subtypes.  We 
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believe this will lead to the ability to narrow down the size of these regions and ultimately 
pinpoint the important oncogenes and tumor suppressors. These models will then serve as in 
vivo experimental systems to explore mechanistically.   
 
A third example of the mouse guiding discovery was the high expression of the 
proliferation cluster seen in common between murine models initiated using T-antigen or 
T121 and human basal-like tumors.  This suggested to us that basal-like tumors may also 
have a defect in the RB-E2F pathway.  We evaluated the RB1 locus and observed that RB1 
LOH varies significantly across human breast tumor subtype.  RB1 LOH occurs at a 
frequency of 72.2% in basal-like breast tumors and 61.5% in Luminal B tumors, both of 
which are in the range of the 60-75% frequency observed in human retinoblastomas[14-17]. 
 
Knockdown of RB1 in established breast cancer cell lines has recently been shown to 
increase sensitivity to a variety of DNA-damaging therapeutic agents[18].  While these 
experiments were performed with ER+ tumor cell lines, it does open the possibility that the 
RB1 defect in basal-like tumors plays a role in their increased chemosensitivity compared to 
luminal tumors.  In recent studies, basal-like tumors have been shown to have a higher 
sensitivity to neoadjuvant chemotherapy, however patients without complete response have a 
poor outcome[19, 20].  Some possibilities among many for the incomplete responders doing 
poorly could reflect the fact that RB1 loss and checkpoint loss can also lead to an increase in 
mutation rate in surviving cells or these tumors could have intact RB1.  Thus a remaining 
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important question is whether RB1 functional status is involved in sensitivity to 
chemotherapy within the basal-like subtype. 
 
Similar to basal-like tumors, Luminal B tumors showed a high frequency (61.5%) of 
RB1 LOH in our study.  In the recent study by Bosco et al., luminal tumor cell lines were 
shown to be more proliferative and resistant to hormone therapy following knockdown of 
RB1[18].  The RB loss signature was shown to be predictive of outcome in a dataset 
containing only ER+ breast tumors treated with tamoxifen monotherapy.  Therefore, the loss 
of RB1 may also play a substantial role in the increased proliferation, possible resistance to 
hormonal therapies, and poor prognosis that is seen in Luminal B tumors as compared to 
Luminal A tumors. 
 
An important caveat to all comparative studies is that there are clear biological 
differences between mice and humans, which may or may not directly impact disease 
mechanisms. A potential example of inherent species difference could be the aforementioned 
biology associated with ER and its downstream pathway. In humans, ER is highly expressed 
in luminal tumors[21], with the luminal phenotype being characterized by the high 
expression of some genes that are ER-regulated like PR and RERG[22], and other luminal 
genes that are likely GATA3-regulated including AGR2 and K8/18[23]. In our original 
mouse model study, ER expression was low to absent in all the tumors we tested, as was the 
expression of most human ER-responsive genes. This finding is consistent with previous 
reports that most late-stage murine mammary tumors are ER-negative ([24] and references 
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within). However, it should be noted that two human luminal tumor-defining genes (XBP1 
and GATA3[23], were both highly expressed in murine luminal tumors. Taken together, these 
data suggest that the human “luminal” profile may actually be a combination of at least two 
profiles, one of which is ER-regulated and another of which is GATA3-regulated.  Support 
for a link between GATA3 and luminal cell origins comes from studies of GATA3 loss in 
mice.  The selective loss of GATA3 in the mammary gland resulted in either a lack of luminal 
cells, or a significant decrease in the number and/or maturation of luminal cells[25, 26].  In a 
recent study it was shown that GATA3’s transcriptional regulation of the ER-alpha gene itself 
is required for estradiol stimulation of cell cycle progression[27].  Reciprocally, ER-alpha 
directly stimulates the transcription of GATA3.  Why and how these mouse tumor models 
express GATA3 without ER is an open question for exploration?  These mouse models may 
also represent a unique opportunity to explore GATA3 function independent of ER.  These 
results suggest that in the mouse models tested, the ER-regulated gene cassette that is present 
in human luminal tumors is missing, and that the GATA3-mediated luminal signature 
remains.  We believe, due to the partial human luminal tumor signature seen in mice, that the 
murine luminal models, especially the TgMMTV-Neu model, best resemble human luminal 
tumors and more specifically luminal B tumors, which are luminal tumors that express low 
amounts of ER and show a poor outcome[4, 5, 28].  
 
A few murine ER-positive mammary tumor models have been developed[29-32].  We 
have analyzed a number of these models and they do not seem to resemble ER+ luminal 
human tumors.  Therefore, the mouse may not be a faithful model in which to study estrogen-
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dependent breast cancer and one may have to turn to the rat as a model.  Many of these 
models constitute a new class of mouse mammary tumors that have alveolar expression 
features, a subtype that does not appear to have a common human correlate. 
 
In a recent population-based epidemiological study, pregnancy was shown to be 
protective for human luminal A tumors with increased parity and younger age at first full-
term pregnancy each showing a reduced risk[33].  On the other hand, pregnancy was shown 
to be associated with basal-like breast cancer with parity and younger age at first full-term 
pregnancy increasing risk.  In another study, increasing age at menarche was associated with 
a reduced risk of basal-like breast cancer[34].  Therefore, it appears that hormone exposure is 
protective against luminal breast cancer but constitutes a risk factor for basal-like breast 
cancer.  Recently, exogenous estrogen and progesterone exposure for short durations was 
shown to be able to mimic the protective effects of pregnancy in two genetically engineered 
mammary tumor models[35].  One of the models used was MMTV-LTR driving the 
activated Neu transgene, similar to the Neu model that we showed had luminal expression 
features in our study.  The other model was the p53 transplant model.  In a separate study, 
targeted conditional ER-alpha overexpression in mammary glands of TgMMTV-Cre;Brca1 
p53, the same mice we showed often have basal features, increased the incidence and number 
of mammary tumors[36].  Many of these tumors were ER-negative even though ER was 
inducibly overexpressed in this model.  Straightforward parity studies cannot be performed in 
many of the mouse models in current use because the MMTV promoter (and WAP) is 
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induced during pregnancy.  However, the results of these studies are promising for modeling 
hormone and other environmental exposures in the mouse with relevance to human subtypes. 
 
One of the key aspects of credentialing a model is to determine if it behaves like its 
human counterpart.  This is particularly important when considering the use of mouse models 
preclinically.  There have been a number of recent success stories of GEMs showing drug 
efficacy including mice with mutant EGFR-induced lung adenocarcinomas responding 
favorably to EGFR-targeted therapies [37, 38].  Our across species comparison showed us 
that the TgMMTV-Neu model exhibits gene expression patterns similar to human luminal 
tumors.  A recent report showed that treatment of this same mouse model with the mTOR 
inhibitor, rapamycin, led to growth arrest and regression of the primary tumors while 
inhibiting proliferation in lung metastases[39].  Taken together, these studies suggest that 
human luminal tumors and especially the subset with HER2 overexpression or PIK3CA or 
PTEN mutations may be particularly sensitive to mTOR inhibitors. 
 
The analyses described here identified many common and biologically relevant 
signatures across tumors of both species. These analyses also confirm the notion that there is 
not a single murine model that can faithfully recapitulate all of the complexities of human 
breast cancer, or even represent a human breast cancer subtype, however, the murine models 
do show shared features with specific human subtypes.  It is these commonalties that have 
provided insights into important tumor biology and laid the groundwork for many future 
studies. 
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Appendix IIA. Complete unsupervised cluster diagram of all mouse tumors. Samples are 
colored according to mouse model from which they were derived, and the genes were 
selected using a variation filter of 3-fold or more on 3 or more samples. 
 
 
APPENDIX IIB 
 
 
 
Appendix IIB. Consensus Clustering (CC) analyses applied to the mouse models. (A) CC 
matrices generated using the 866 gene mouse intrinsic list, by cluster numbers K=2 through 
K=15.  (B) Empirical Cumulative Distribution (CDF) plot corresponding to the consensus 
matrices in the range K=2 to 15.  (C) CC directly compared to the hierarchical clustering-
based results. The dendrogram from Figure 1 (using the intrinsic gene set) is shown and 
immediately below is a colored matrix showing sample assignments based upon the various 
number of K clusters from the CC. By comparison, the analysis performed on the mouse 
dataset using all genes (bottom matrix) is presented. 
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APPENDIX IIC 
 
 
 
Appendix IIC. Histological characterization of six different human “claudin-low” tumors 
using H&E sections. 
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APPENDIX IID 
 
Appendix IID. Gene Set Enrichment Analysis (GSEA) of murine pathway models versus 5 
human subtypes. Statistically significant findings are highlighted in bold. 
 
 
Is Class 
    BASAL-like LUMINAL HER2+/ER- NORMAL claudin-LOW 
Mouse 
Model 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER
p-val 
T-antigen 
models 406 0 0.002 - - - - - - - - 
BRCA1 
models 427 0.004 0.0881 - - - - - - - - 
Wnt1 
model 34 0.1159 0.5215 - - 0.1741 0.6356 0.0629 0.2553 - - 
Myc.model 517 0.1438 0.6086 - - 0.4553 0.948 - - - - 
BRCA1 
p53 IR 
model 65 0.1957 0.6867 - - - - 0.3354 0.8739 - - 
Int3 model 137 0.283 0.8428 - - 0.1706 0.7417 0.0278 0.3904 - - 
Neu.model 460 - - 0.0061 0.154 0.1594 0.6847 0.9014 0.997 - - 
            
            
Is Not Class 
    BASAL-like LUMINAL HER2+/ER- NORMAL claudin-LOW 
Mouse 
Model 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER
p-val 
T-antigen 
models 406 - - 0.043 0.087 0.899 0.999 0.06831 0.207 0.5962 0.996 
BRCA1 
models 427 - - 0.1037 0.52 0.5203 0.968 0.14 0.605 0.7519 0.997 
Wnt1 
model 34 - - 0.01734 0.113 - - - - 0.2417 0.787 
Myc.model 517 - - 0.126 0.557 - - 0.7692 0.998 0.278 0.85 
BRCA1 
p53 IR 
model 65 - - 0.5198 0.966 0.6536 0.991 - - 0.1063 0.499 
Int3 model 137 - - 0.1996 0.799 - - - - 0.2079 0.83 
Neu.model 460 0 0.027 - - - - - - 0.4188 0.939 
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APPENDIX IIE 
 
Appendix IIE. Gene Set Enrichment Analysis (GSEA) of 10 murine classes versus clinical 
ER status and HER2 status in ER negative patients. Statistically significant findings are 
highlighted in bold. 
 
Is Class 
    ER + ER- / HER2- ER- / HER2+ 
Mouse Class 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
I 1882 0.2267 0.795 - - 0.9243 0.997 
II 912 - - - - 0.5675 0.988 
III 143 0.7919 0.999 - - 0.2723 0.837 
IV 1019 - - 0.0062 0.323 - - 
V 34 - - 0.668 0.994 0.4929 0.964 
VI 820 0.0098 0.174 - - 0.6111 0.976 
VII 851 - - 0.1417 0.618 0.5666 0.975 
VIII 236 0.3379 0.922 - - 0.1244 0.73 
IX 462 - - 0 0.009 0.8112 0.998 
X 338 - - 0 0.003 - - 
        
        
Is Not Class 
    ER + ER- / HER2- ER- / HER2+ 
Mouse Class 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
I 1882 - - 0.0829 0.522 - - 
II 912 0.7182 0.999 0.7589 1 - - 
III 143 - - 0.5337 0.978 - - 
IV 1019 0.012 0.469 - - 0.3107 0.909 
V 34 0.5571 0.985 - - - - 
VI 820 - - 0.0041 0.061 - - 
VII 851 0.1726 0.675 - - - - 
VIII 236 - - 0.2432 0.873 - - 
IX 462 0.00641 0.024 - - - - 
X 338 0.00641 0.043 - - 0.6922 0.999 
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APPENDIX IIF 
 
Appendix IIF. Gene Set Enrichment Analysis (GSEA) of murine pathway models versus 
clinical ER status and HER2 status in ER negative patients. Statistically significant findings 
are highlighted in bold. 
 
Is Class 
    ER + ER- / HER2- ER- / HER2+ 
Mouse Model 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
T-antigen models 406 - - 0 0.003 - - 
BRCA1 models 427 - - 0.0061 0.116 0.7755 0.993 
Wnt1 model 34 - - 0.4073 0.938 0.2478 0.775 
Myc.model 517 - - 0.1253 0.573 0.5506 0.975 
BRCA1 p53 IR 
model 65 - - 0.6159 0.993 0.5648 0.971 
Int3 model 137 0.1988 0.818 - - - - 
Neu.model 460 0.0078 0.185 - - 0.5479 0.965 
        
        
Is Not Class 
    ER + ER- / HER2- ER- / HER2+ 
Mouse Model 
# 
genes 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
NOM 
p-val 
FWER 
p-val 
T-antigen models 406 0.0106 0.022 - - 0.8453 1 
BRCA1 models 427 0.0098 0.17 - - - - 
Wnt1 model 34 0.3252 0.858 - - - - 
Myc.model 517 0.1206 0.604 - - - - 
BRCA1 p53 IR 
model 65 0.6063 0.985 - - - - 
Int3 model 137 - - 0.3202 0.899 0.5552 0.978 
Neu.model 460 - - 0.002 0.079 - - 
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APPENDIX VA 
 
Appendix VA.  ANOVA box plot comparison of mRNA expression and protein staining 
in breast tumors.  A) shows low RB1 mRNA expression correlates with low RB1 protein 
expression and B)  high p16INK4a mRNA expression correlates with high protein 
expression. 
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APPENDIX VB 
 
Appendix VB.  p16INK4a expression in mouse models of breast cancer. 
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APPENDIX VC 
 
Appendix VC.  Comparison of overlap between 3 gene lists using hypergeometric mean 
analysis. 
 
 
Overlap of population of RB-LOH and RB-regulated-inclusive:  7722 genes  
RB-LOH in the overlap:  270 genes  
RB-regulated-inclusive in the overlap: 119 genes  
Overlap of RB-LOH and RB-regulated-inclusive in the overlap of the  
population: 42 genes  
 
phyper(42,270,(7722-270),119)  
p-value < 0.001  
 
++++++++++++++++++++++++++++++++++++++++++++++++++++++++  
 
Overlap of population of RB-regulated-inclusive and V12:   8381 genes  
RB-regulated-inclusive in the overlap:  115 genes  
V12-Prolif in the overlap: 119 genes  
Overlap of RB-regulated-inclusive and V12-Prolif in the overlap of  
the population: 27 genes  
 
phyper(27,115,(8381-115),119)  
p-value < 0.001 
 
+++++++++++++++++++++++++++++++++++++++++++++++++++++++  
 
Overlap of population of RB-LOH and V12:  10407 genes  
RB-LOH in the overlap:  329 genes  
V12-Prolif in the overlap: 137 genes  
Overlap of RB-LOH and V12-Prolif in the overlap of the population: 68 genes  
 
phyper(68,329,(10407-329),137)  
p-value < 0.001 
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APPENDIX VD 
 
Appendix VD.  The expression of RB-loss signature is highest in basal-like tumors. 
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